Page last updated: 2024-12-08

homoharringtonine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Homoharringtonine: Semisynthetic derivative of harringtonine that acts as a protein synthesis inhibitor and induces APOPTOSIS in tumor cells. It is used in the treatment of MYELOID LEUKEMIA, CHRONIC. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

omacetaxine mepesuccinate : A cephalotaxine-derived alkaloid ester obtained from Cephalotaxus harringtonia; used for the treatment of chronic or accelerated phase chronic myeloid leukaemia. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
CephalotaxusgenusA plant genus of the family TAXACEAE, order Pinales, class Pinopsida, division TRACHEOPHYTA. Members contain homoharringtonine.[MeSH]TaxaceaeA plant family of the order Pinales, class Pinopsida, division TRACHEOPHYTA.[MeSH]

Cross-References

ID SourceID
PubMed CID285033
CHEMBL ID46286
CHEBI ID71019
SCHEMBL ID12745687
MeSH IDM0041919

Synonyms (90)

Synonym
HMS3267H22
BRD-K76674262-001-01-7
26833-87-4
nsc-141633
homoharringtonine
nsc141633 ,
cgx-635-14 (formulation)
tekinex
cgx-635
omapro
HHT ,
myelostat
ceflatonin
omacetaxine mepesuccinate
zj-c
brn 5687925
nsc 141633
cephalotaxine, 4-methyl-, 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester)
c29h39no9
NCGC00025155-01
cephalotaxine, 4-methyl (2r)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester)
MLS001424293
smr000469230
NCI60_000917
CHEMBL46286
chebi:71019 ,
homoharringtonin
omacetaxine mepesuccinate (usan)
synribo (tn)
D08956
NCGC00025155-04
NCGC00025155-02
NCGC00025155-03
synribo
6fg8041s5b ,
unii-6fg8041s5b
1-((1s,3ar,14bs)-2-methoxy-1,5,6,8,9,14b-hexahydro-4h- cyclopenta(a)(1,3)dioxolo(4,5-h)pyrrolo(2,1-b)(3)benzazepin-1-yl) 4-methyl (2r)-2- hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate
omacetaxine mepesuccinate [usan:inn]
dtxcid8025678
omacetaxine mepesuccinate [usan]
omacetaxine mepesuccinate [inn]
omacetaxine mepesuccinate [mart.]
omacetaxine mepesuccinate [vandf]
homoharringtonine [mi]
omacetaxine mepesuccinate [who-dd]
omacetaxine mepesuccinate [orange book]
1-[(1s,3ar,14bs)-2-methoxy-1,5,6,8,9,14b-hexahydro-4h-cyclopenta[a][1,3]dioxolo[4,5-h]pyrrolo[2,1-b][3]benzazepin-1-yl] 4-methyl (2r)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate
omacetaxini mepesuccinas
(-)-homoharringtonine
mepesuccinate d'omacetaxine
mepesuccinato de omacetaxina
(2'r,3s,4s,5r)-(-)-homoharringtonine
S9015
cephalotaxine 4-methyl (2r)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester)
AB00642561-02
DB04865
HY-14944
NC00395
gtpl7454
H1775
SCHEMBL12745687
cephalotaxine 4-methyl (2r)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate
HB4660
AKOS024456585
SR-01000597562-1
sr-01000597562
bdbm50480293
homoharringtonine, >=98% (hplc)
omacetaxine (homoharringtonine)
mfcd05618221
HYFHYPWGAURHIV-JFIAXGOJSA-N
HMS3678N03
HMS3414N05
Q7089373
BRD-K76674262-001-02-5
1-o-[(2s,3s,6r)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-o-methyl (2r)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate
AMY33459
CCG-269981
omacetaxine mepesuccinate;hht
NCGC00025155-07
cephalotaxine, o3-((2r)-2,6-dihydroxy-2-(2-methoxy-2-oxoethyl)-6-methyl-1-oxoheptyl)-
nsc758253
cephalotaxine, 3-[4-methyl (2r)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate]
nsc-758253
(s)-1-((11bs,12s,14ar)-13-methoxy-2,3,5,6,11b,12-hexahydro-1h-[1,3]dioxolo[4',5':4,5]benzo[1,2-d]cyclopenta[b]pyrrolo[1,2-a]azepin-12-yl) 4-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)succinate
(2s,3s,6r)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0^{2,6}.0^{6,10}.0^{15,19}]icosa-1(13),4,14,19-tetraen-3-yl 1-methyl (3r)-3-hydroxy-3-(4-hydroxy-4-methylpentyl)butanedioate
EN300-22161068
omacetaxine mepesuccinate (mart.)
1-((1s,3ar,14bs)-2-methoxy-1,5,6,8,9,14b-hexahydro-4h-cyclopenta(a)(1,3)dioxolo(4,5-h)pyrrolo(2,1-b)(3)benzazepin-1-yl) 4-methyl (2r)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate
l01xx40

Research Excerpts

Overview

Homoharringtonine (HHT) is a first-in-class inhibitor of protein biosynthesis. FDA-approved for the treatment of chronic myeloid leukemia (CML) that is resistant to at least two TKIs.

ExcerptReferenceRelevance
"Homoharringtonine (HHT) is an antitumor reagent with anti-inflammatory activity."( Homoharringtonine Inhibits Alzheimer's Disease Progression by Reducing Neuroinflammation via STAT3 Signaling in APP/PS1 Mice.
Jiang, X; Wang, M; Wu, Q; Zhang, C, 2021
)
2.79
"Homoharringtonine (HHT) is a first-in-class inhibitor of protein biosynthesis and is FDA-approved for the treatment of chronic myeloid leukemia (CML) that is resistant to at least two TKIs."( Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability.
Ali, AA; Amankulor, NM; Duensing, A; Kaczorowski, A; Lee, DM; Liu, C; Liu, L; Patil, SS; Presutti, LD; Rao, AV; Rausch, JL; Schneider, F; Shuda, M; Sun, A; Trent, PT, 2022
)
1.44
"Homoharringtonine (HHT) is an FDA-approved, naturally-derived drug with known anti-leukemic properties, but its precise mechanisms of action remain incompletely understood."( Mitochondrial complex I inhibition by homoharringtonine: A novel strategy for suppression of chronic myeloid leukemia.
Cui, G; Di, L; Han, H; Liu, M; Meng, F; Mingyuen Lee, S; Wang, G; Wang, L; Zhang, Q; Zhang, Y; Zhao, C; Zhu, H, 2023
)
1.9
"Homoharringtonine (HHT) is an approved treatment for adult patients with chronic‑ or accelerated‑phase CML who are resistant to TKIs and other therapies; however, the underlying mechanisms remain unclear."( Homoharringtonine promotes BCR‑ABL degradation through the p62‑mediated autophagy pathway.
Bo, Z; Jiang, Y; Li, S; Song, X; Tong, Y; Wang, C, 2020
)
2.72
"Homoharringtonine (HHT) is a classical anti-leukaemia drug with high sensitivity to FLT3-ITD AML cells."( Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
Cui, Y; Guo, T; Guo, Y; Huang, J; Liu, X; Luo, H; Naren, D; Qu, Y; Wang, F; Wei, H; Yang, Y; Zhang, D; Zhang, L; Zheng, Y, 2021
)
2.79
"Homoharringtonine(HHT) is an alkaloid with anti-tumor activity, having a good therapeutic effect on chronic myeloid leukemia(CML), and its toxicity is much lower than other anti-cancer drugs. "( [Research Progress of Homoharringtonine Effect on IM-resistant Chronic Myelogenous Leukemia -Review].
Li, YF; Wang, Q, 2017
)
2.21
"Homoharringtonine (HHT) is a known anti-leukemia drug that inhibits MM both in vitro and in vivo."( Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts.
Chen, P; Cheng, Y; Hou, D; Huang, H; Wen, X; Xie, J; Yang, H; You, P; Yuan, Q, 2017
)
2.62
"Homoharringtonine (HHT) is a known anti-leukemia drug that inhibits multiple myeloma (MM) cells both in vitro and in vivo. "( PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft.
Chen, P; Hou, D; Huang, H; Wang, B; Wen, X; Xie, J; Yang, H; Yuan, Q; Zou, H, 2018
)
2.19
"Homoharringtonine (HHT) is a natural alkaloid with potent antitumor activity, but its precise mechanism of action is still poorly understood."( Homoharringtonine regulates the alternative splicing of Bcl-x and caspase 9 through a protein phosphatase 1-dependent mechanism.
Fu, Q; Li, B; Li, J; Li, S; Liu, SS; Lu, D; Song, J; Su, Z; Sun, Q; Wang, Z, 2018
)
3.37
"Homoharringtonine is an alkaloid inhibitor of protein synthesis with activity in myeloid malignancies. "( A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome.
Cortes, JE; Daver, N; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Kantarjian, HM; Kornblau, S; Vega-Ruiz, A; Verstovsek, S, 2013
)
2.07
"Homoharringtonine/omacetaxine is a unique agent with a long history of research development. "( Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval.
Cortes, J; Kantarjian, HM; O'Brien, S, 2013
)
3.28
"Homoharringtonine (HHT) is a kind of cephalotaxus alkaloid used in traditional Chinese medicine. "( MiR-370 sensitizes chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead box M1.
Chen, C; Fu, Y; Guo, Q; Huang, T; Jia, J; Shen, H; Wang, L; Wang, X; Zeng, J; Zhou, M, 2013
)
2.08
"Homoharringtonine injection is a preparation for acute nonlymphocytic leukemia, which is approved by China Food and Drug Administration (CFDA) and US Food and Drug Administration."( Screening of allergic components mediated by H(1)R in homoharringtonine injection through H(1)R/CMC-HPLC/MS.
Cao, J; Guo, Y; Han, S; Liu, Q; Zhang, T, 2014
)
1.37
"Homoharringtonine (HHT) is a natural alkaloid isolated from various Cephalotaxus species. "( Homoharringtonine binds to and increases myosin-9 in myeloid leukaemia.
Jin, J; Lu, S; Shen, S; Yin, X; Zhang, T; Zheng, J; Zhu, Z, 2016
)
3.32
"As homoharringtonine is a clinically approved antileukemia drug, and ABT-199 is in advanced phases of diverse clinical trials, our data might have direct implications for novel concepts of early clinical trials in patients with aggressive DLBCL."( Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.
Alam, M; Andera, L; Benesova, S; Brazina, J; Helman, K; Jaksa, R; Klanova, M; Klener, P; Kodet, R; Lateckova, L; Maswabi, BC; Molinsky, J; Prukova, D; Pytlik, R; Soukup, J; Svadlenka, J; Trneny, M; Vejmelkova, D; Vockova, P, 2016
)
1.31
"Homoharringtonine (HHT) is a natural alkaloid that is obtained from various Cephalotaxus species. "( Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009.
Cortes, J; Kantarjian, H; Quintás-Cardama, A, 2009
)
3.24
"Homoharringtonine (HHT) is a plant alkaloid that inhibits the elongation phase of translation that is currently in clinical trials. "( Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia.
Chen, R; Chen, Y; Guo, L; Jiang, Y; Plunkett, W; Wierda, WG, 2011
)
3.25
"Homoharringtonine (HHT) is an ester of cephalotaxine (CET), both of which derive from the Chinese coniferous tree Cephalotaxus hainanensis. "( Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines.
Efferth, T; Gebhart, E; Halatsch, ME; Ross, DD; Sauerbrey, A, 2003
)
2.02
"Homoharringtonine (HHT) is a plant alkaloid with antileukemia activity that is currently being used for treatment of acute, chronic leukemias and MDS. "( Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP).
Jie, J; Weilai, X; Xiangming, T; Yinjun, L, 2004
)
3.21
"Homoharringtonine (HHT) is a cephalotaxine ester derived from an evergreen tree found wildely throughout southern China, which has antileukemic activities against a variety of acute myeloid leukemic cells. "( Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells.
Lin, MF; Mai, WY, 2005
)
2.07
"Homoharringtonine (HHT) is a cephalotaxus alkaloid that inhibits the synthesis of proteins leading to apoptosis. "( Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
Cortes, J; Estrov, Z; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Ladie, N; Murgo, A; O'Brien, S; Quintás-Cardama, A; Verstovsek, S, 2007
)
2.06
"Homoharringtonine (HHT) is a plant alkaloid with antileukemic activity which is currently being used for treatment of acute and chronic leukemias. "( Homoharringtonine induces apoptosis and growth arrest in human myeloma cells.
Jin, J; Lou, YJ; Qian, WB, 2007
)
3.23
"Homoharringtonine is a cephalotaxine ester derived from Cephalotaxus harringtonia, which is a Chinese evergreen tree. "( Phase I clinical investigation of homoharringtonine.
Ajani, JA; Bodey, GP; Ewer, M; Keating, M; Legha, SS; Picket, S, 1984
)
1.99
"Homoharringtonine (HHT) is a plant alkaloid with potent myelosuppressive activity and little toxicity when used in a continuous infusion schedule. "( Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.
Andreeff, M; Beran, M; Hester, J; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Rios, MB; Robertson, LE; Talpaz, M, 1995
)
3.18
"Homoharringtonine (HHT) is a new drug with antileukemic activity which is currently tested for treatment of acute and chronic leukemias, either alone or in combination with other agents. "( MDR-related P170-glycoprotein modulates cytotoxic activity of homoharringtonine.
Baccarani, M; Candoni, A; Damiani, D; Marie, JP; Melli, C; Michelutti, A; Michieli, MG; Russo, D; Zhou, DC; Zittoun, R, 1995
)
1.97
"Homoharringtonine (HHT) is a novel cephalotaxime alkaloid with reported efficacy in relapsed and de novo AML and more recently, chronic myeloid leukemia."( Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia.
Ahmed, T; Arlin, ZA; Baskind, P; Feldman, EJ; Seiter, KP, 1996
)
2.46
"Homoharringtonine (HHT) is a cytotoxic alkaloid isolated from the evergreen tree cephalotaxus harringtonia native to the southern provinces of China. "( Homoharringtonine: an effective new natural product in cancer chemotherapy.
Marie, JP; Zhou, DC; Zittoun, R, 1995
)
3.18
"Homoharringtonine (HHT) is a cephalotaxine alkaloid that showed clinical efficacy in the chronic phase of chronic myeloid leukemia (Ph1+CML). "( Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors.
Baccarani, M; Damiani, D; Manfroi, S; Michelutti, A; Ottaviani, E; Russo, D; Tosi, P; Tura, S; Visani, G, 1997
)
2.13
"Homoharringtonine (HHT) is a novel plant alkaloid that produced a complete hematologic remission (CHR) in 72% of patients with late chronic phase chronic myelogenous leukemia (CML). "( Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.
Andreeff, M; Beran, M; Cheson, B; Feldman, E; Freireich, E; Giralt, S; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Rios, MB; Talpaz, M, 1999
)
2.14
"Homoharringtonine (HHT) is a potent myelosuppressive agent and has antitumor activity. "( Stability-indicating LC assay of and impurity identification in homoharringtonine samples.
Cheung, AP; Fang, K; He, J; Liu, P; Nguyen, N; Struble, E; Wang, E, 2000
)
1.99
"Homoharringtonine (HHT) is a plant alkaloid that is derived from a Chinese evergreen tree. "( A phase II study of Homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: a pediatric oncology group study.
Bell, BA; Chang, MN; Weinstein, HJ, 2001
)
2.08
"Homoharringtonine (HHT) is a cephalotaxine alkaloid with reported efficacy in acute myelogenous leukemia (AML). "( Homoharringtonine is safe and effective for patients with acute myelogenous leukemia.
Ahmed, T; Arlin, Z; Baskind, P; Chun, H; Cook, P; Feldman, E; Mittelman, A; Puccio, C, 1992
)
3.17
"Homoharringtonine (HHT) is a cephalotaxine ester derived from an evergreen tree of southern China. "( Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro.
Chen, DL; Koeffler, HP; Shen, ZS; Zhou, JY, 1990
)
2.12
"Homoharringtonine (HHT) is a new plant alkaloid originally isolated in the People's Republic of China. "( Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia.
Coonley, CJ; Gee, TS; Warrell, RP, 1985
)
3.15

Effects

Homoharringtonine (HHT) has been used for hematologic malignancies for over 40 years in China and was approved by the FDA approximately 10 years ago. The clinical therapeutic effect is significant but the working mechanism is poorly understood.

ExcerptReferenceRelevance
"Homoharringtonine (HHT) has been used for hematologic malignancies for over 40 years in China and was approved by the FDA approximately 10 years ago."( Inhibition of bladder cancer growth with homoharringtonine by inactivating integrin α5/β1-FAK/Src axis: A novel strategy for drug application.
Chen, P; Kwok, HF; Li, J; Lin, Z; Wu, Q; Zhang, Q, 2023
)
1.9
"Homoharringtonine (HHT) has been used as an antileukemia agent in the clinic which processes a high-potential therapeutic efficacy against multiple myeloma (MM). "( Homoharringtonine Exerts an Antimyeloma Effect by Promoting Excess Parkin-Dependent Mitophagy.
Cui, X; Huang, N; Xu, J; Zhang, Y; Zheng, W, 2020
)
3.44
"Homoharringtonine (HHT) has been reported to have positive effects in preventing various kinds of fibrosis."( Homoharringtonine inhibits fibroblasts proliferation, extracellular matrix production and reduces surgery-induced knee arthrofibrosis via PI3K/AKT/mTOR pathway-mediated apoptosis.
Dai, J; Jiang, Q; Jiao, R; Sun, Y; Wang, J, 2021
)
2.79
"Homoharringtonine (HHT) has long and widely been used in China for the treatment of acute myeloid leukemia (AML), the clinical therapeutic effect is significant but the working mechanism is poorly understood. "( Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells.
Chen, J; Jin, J; Li, C; Li, X; Lu, D; Mu, Q; Suo, S; Yin, X; Yu, M; Zhou, J; Zhou, Y, 2017
)
3.34
"Homoharringtonine (HHT) has been reported to be effective in a portion of patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML). "( Bcl-xL is a dominant antiapoptotic protein that inhibits homoharringtonine-induced apoptosis in leukemia cells.
Jing, Y; Wang, R; Yin, S; Zhang, H; Zhou, F, 2011
)
2.06
"Homoharringtonine (HHT) has currently been used successfully in the treatment of acute and chronic myeloid leukemias and has been shown to induce apoptosis of different types of leukemic cells in vitro. "( Homoharringtonine induces apoptosis of endothelium and down-regulates VEGF expression of K562 cells.
Lin, MF; Ye, XJ, 2004
)
3.21
"Homoharringtonine has been shown to lead to apoptosis of leukemic cells in several studies. "( Homoharringtonine-induced apoptosis of MDS cell line MUTZ-1 cells is mediated by the endoplasmic reticulum stress pathway.
Donghua, H; Jie, H; Liang, G; Wenjun, W; Xiaoyan, H; Xingkui, X; Zhen, C, 2007
)
3.23
"Homoharringtonine (HHT) has substantial cytotoxic activity against cell lines of experimental tumors. "( Phase I trial of homoharringtonine administered as a 5-day continuous infusion.
Coonley, CJ; Warrell, RP; Young, CW,
)
1.91
"Homoharringtonine has relatively mild extramedullary toxicities and no anthracycline-like cardiac toxicity, which make it a suitable candidate for the treatment of aged patients."( Homoharringtonine: an effective new natural product in cancer chemotherapy.
Marie, JP; Zhou, DC; Zittoun, R, 1995
)
2.46
"Homoharringtonine (HHT) has antileukemic activity in patients with Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML). "( Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
Andreeff, M; Beth, M; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Keating, M; Koller, C; Kornblau, S; Mallard, S; Murgo, A; O'Brien, S; Shan, J; Talpaz, M; Thomas, D, 2002
)
2.13
"Homoharringtonine (HHT) has been reported to induce hyperglycemia. "( Homoharringtonine-induced hyperglycemia.
Lobell, M; Ogden, W; Stewart, JA; Sylvester, RK, 1989
)
3.16

Actions

ExcerptReferenceRelevance
"Homoharringtonine was shown to inhibit the formation of diphenylalanine and acetylphenylalanyl-puromycin catalysed by human and rat liver ribosomes, but was inactive as an inhibitor on the E."( Selective inhibition of the polypeptide chain elongation in eukaryotic cells.
Ajtkhozhina, NA; Fedorova, OS; Graifer, DM; Karpova, GG; Matasova, NB; Odintsov, VB; Tujebajeva, RM, 1992
)
1

Treatment

ExcerptReferenceRelevance
"Homoharringtonine treatment repressed enhancers and their BRD4 occupancy and was associated with reduced levels of c-Myc, c-Myb, MCL1, and Bcl-xL."( Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
Bhalla, KN; Birdwell, C; Borthakur, G; Daver, N; Davis, JA; DiNardo, CD; Fiskus, W; Green, MR; Kadia, TM; Khoury, JD; Kornblau, SM; Mill, CP; Ohanian, M; Qi, Y; Short, N; Su, X; Takahashi, K, 2022
)
1.44

Toxicity

ExcerptReferenceRelevance
" There was no significant difference in drug-related adverse events between treatment arms."( High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China.
Huang, BT; Liu, XL; Xiao, Z; Yu, J; Zeng, QC; Zhu, HQ, 2012
)
0.78
"HAA regimen may be an efficacious and safe regimen with a good toleration in the induction therapy for newly diagnosed AML, and a high CR rate could be achieved with only one or two courses."( [The efficacy and safety of HAA regimen as induction chemotherapy in 150 newly diagnosed acute myeloid leukemia].
Huang, J; Jin, J; Mai, WY; Mao, LP; Meng, HT; Qian, JJ; Qian, WB; Song, YP; Tong, HY; Tong, Y; Xu, WL, 2011
)
0.37
"These data suggest that the CHG priming regimen is effective and safe as a novel induction therapy for elderly patients with high-risk MDS and MDS-AML."( Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.
Chang, C; He, Q; Li, X; Pu, Q; Su, J; Wu, L; Zhang, X, 2011
)
0.61
" The adverse event profile is manageable and with subcutaneous administration at the approved dose, cardiac toxicity is no longer a concern."( A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
Assouline, SE; Damlaj, M; Lipton, JH, 2016
)
0.43
"The CHG priming regimen provided a safe and effective salvage regimen for higher risk MDS patients who were resistant to decitabine."( The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine.
Chang, C; He, Q; Li, X; Song, L; Su, J; Tao, Y; Wu, D; Wu, L; Xiu, C; Xu, F; Zhang, Z; Zhao, Y; Zhou, L, 2019
)
0.74
"SOME was safe and effective for R/R and newly diagnosed FLT3-ITD AML."( Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Au, CH; Chan, TL; Ip, HW; Kwong, YL; Lam, SSY; Lau, JSM; Lee, HKK; Leung, AYH; Leung, GMK; Li, W; Luk, TH; Ma, ESK; Ng, NKL; Tsui, SP; Yang, N; Yip, SF; Zhang, C, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
"To determine the maximum-tolerated dose (MTD), dose-limiting toxicities and pharmacokinetic of semisynthetic homoharringtonine (ssHHT), given as a twice daily subcutaneous (s."( A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia.
Bardin, C; Chaoui, D; Chast, F; Chevret, S; Legrand, O; Lévy, V; Marie, JP; Raffoux, E; Rio, B; Rousselot, P; Sentenac, S; Vekhoff, A; Zohar, S, 2006
)
0.77
" Methods The study comprised a 7-days pharmacokinetic assessment followed by a treatment period of ≤ six 28-days cycles."( Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors.
Beijnen, JH; Hellriegel, E; Hershock, D; Huitema, AD; Lucas, L; Mergui-Roelvink, M; Munteanu, M; Nijenhuis, CM; Rabinovich-Guilatt, L; Robertson, P; Rosing, H; Schellens, JH; Spiegelstein, O, 2016
)
0.43

Compound-Compound Interactions

Homoharringtonine combined with aclarubicin and cytarabine (HAA) is a highly effective treatment for acute myeloid leukemia (AML), especially for t(8;21) AML. Study aimed to explore the effect of homohrringtonine in combination with AG490 on JAK2-STAT5 associated signal pathway in HEL cells.

ExcerptReferenceRelevance
" As a single agent, it resulted in effectively controlling leukocytosis and in producing sporadic karyotypic conversions; its clinical use in combination with interferon (IFN-alpha) for the treatment of CML could thus be considered."( Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors.
Baccarani, M; Damiani, D; Manfroi, S; Michelutti, A; Ottaviani, E; Russo, D; Tosi, P; Tura, S; Visani, G, 1997
)
0.69
" The cytotoxic effects of STI571 were studied in combination with antileukemic agents against Ph(+) leukemia cell lines, KU812, K-562, TCC-S, and TCC-Y."( In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.
Akutsu, M; Furukawa, Y; Honma, Y; Kano, Y; Mano, H; Sato, Y; Tsunoda, S, 2001
)
0.31
" In this paper, we analyzed effectiveness of Glivec in combination with homoharringtonine (HHT) and cytarabine (Ara-C) for patients with Ph chromosome positive acute leukemia (Ph(+)-AL), and investigated patients' tolerance to side effects of this trial."( [Glivec in combination with HA regimen for treatment of 20 patients with Ph chromosome positive acute leukemia].
Huang, F; Liu, XL; Meng, FY; Song, LL; Xu, B; Zhang, Y; Zheng, WY, 2003
)
0.55
"Regimen of Glivec in combination with HA could increase chemotherapy effect for the patients with Ph(+)-AL, prolong their life time and the side-effects were tolerable."( [Glivec in combination with HA regimen for treatment of 20 patients with Ph chromosome positive acute leukemia].
Huang, F; Liu, XL; Meng, FY; Song, LL; Xu, B; Zhang, Y; Zheng, WY, 2003
)
0.32
"To explore the effect of low dose of homoharringtonine (HHT) and cytarabine (Ara-c) combined with granulocyte colony-stimulating factor (G-CSF) priming (HAG regimen) on relapsed or refractory acute myeloid leukemia (AML)."( Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia.
Cao, XM; Chen, YX; Gu, LF; He, AL; Liu, J; Ma, XR; Wang, FX; Zhang, WG, 2011
)
1.02
"This study was aimed to explore the effect of homoharringtonine in combination with AG490 on JAK2-STAT5 associated signal pathway in HEL cells, and analyze its mechanism so as to provide theoretical basis for therapy of chronic myeloproliferative neoplasma by new program."( [Effect of homoharringtonine combined with AG490 on JAK2-STAT5 associated signal pathway in HEL cells].
Ren, YL; Tong, HY, 2011
)
1.02
" The down-regulation of β-catenin expression in group of IFN-α combined with HHT was higher significantly than that in HHT group (0."( [Effects of interferon-α combined with homoharringtonine on K562 cell proliferation and β-catenin expression].
Cao, WK; Deng, ZK; Feng, WT; Guo, H; Li, YF; Liu, XN; Shi, YY; Ye, LL; Zhu, JB, 2012
)
0.65
"To evaluate the efficacy of interferon-α (IFN-α) combined with homoharringtonine (HHT) in the treatment of patients with newly diagnosed chronic-phase chronic myelogenous leukemia (CML), an IFN-α combined with HHT scheme was used as induction and maintenance therapy for 42 patients with CML in chronic phase."( Long-term effect of interferon-α combined with homoharringtonine on chronic myelogenous leukemia in chronic phase.
Ding, B; Li, Y; Zhu, J, 2013
)
0.89
"To study the clinical outcome, adverse effect and treatment cost of homoharringtonine (HHT) in combination with all-trans retinoic acid (ATRA) and arsenic trioxide (AS2O3) for newly diagnosed with patients acute promyelocytic leukemia (APL)."( [Clinical investigation of homoharringtonine in combination with all-transretinoic acid and arsenic trioxide for acute promyelocytic leukemia].
Cao, JJ; Chen, D; Chen, LG; Du, XH; Fan, Z; Li, SY; Lin, L; Liu, XH; Ma, JX; Pei, RZ; Sha, KY; Shi, XW; Tang, SH; Wu, JY; Ye, PP; Zhang, BB; Zhang, PS; Zhuang, XX, 2013
)
0.92
"HHT in combination with ATRA and AS2O3 regimen for newly diagnosed APL has a better efficacy, a higher long-term survival rate, and a lower costs, which is one of the reasonable choice."( [Clinical investigation of homoharringtonine in combination with all-transretinoic acid and arsenic trioxide for acute promyelocytic leukemia].
Cao, JJ; Chen, D; Chen, LG; Du, XH; Fan, Z; Li, SY; Lin, L; Liu, XH; Ma, JX; Pei, RZ; Sha, KY; Shi, XW; Tang, SH; Wu, JY; Ye, PP; Zhang, BB; Zhang, PS; Zhuang, XX, 2013
)
0.69
"To explore the therapeutic effect of homoharringtonine (HHT) combined with cytarabine (HA regimen) on CML-MBC and its influence on bone marrow CD34+CD7+ cells."( Homoharringtonine combined with cytarabine to treat chronic myelogenous leukemia in myeloid blast crisis and its impact on bone marrow CD34+CD7+ cells.
Deng, Z; Ding, B; Li, Y; Shi, Y; Zho, J, 2014
)
2.12
" A total of 56 elderly patients with de novo AML were treated with homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor (HCG)."( Low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor for elderly patients with de novo acute myeloid leukemia.
Chen, C; Xu, W; Yang, J, 2015
)
1.07
"As sensitization of leukemia cells with granulocyte colony-stimulating factor (G-CSF) can enhance the cytotoxicity of chemotherapy in myeloid malignancies, a pilot study was conducted in order to evaluate the effect of G-CSF priming combined with low-dose chemotherapy in patients with higher risk myelodysplastic syndrome (MDS)."( Effect of granulocyte colony-stimulating factor priming combined with low-dose cytarabine and homoharringtonine in higher risk myelodysplastic syndrome patients.
Cao, XM; Chen, YX; Gu, LF; He, AL; Wang, FX; Wang, JL; Yang, Y; Zhang, PY; Zhang, WG; Zhao, WH, 2016
)
0.65
"Homoharringtonine combined with aclarubicin and cytarabine (HAA) is a highly effective treatment for acute myeloid leukemia (AML), especially for t(8;21) AML."( Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase-3-mediated cleavage of the AML1-ETO oncoprotein.
Cao, J; Chen, C; Chen, W; Ding, NN; Feng, H; Niu, MS; Qiu, TT; Wu, QY; Xu, KL; Zhu, HH, 2016
)
3.32
"To explore the effects of homoharringtonine (HHT) alone or combined with imatinib (IM) on K562 cell proliferation and apoptosis, as well as the mRNA and protein expression of BCL6."( [Effects of Homoharringtonine Combined with Imatinib on K562 Cell Apoptosis and BCL6 expression].
Ding, W; Ding, YH; Li, YF; Wang, Q; Wu, JJ, 2016
)
1.11
" The effect of drug combination showed that BCL6 protein significantly down-regulated(P<0."( [Effects of Homoharringtonine Combined with Imatinib on K562 Cell Apoptosis and BCL6 expression].
Ding, W; Ding, YH; Li, YF; Wang, Q; Wu, JJ, 2016
)
0.81
"To explore the effect of homoharringtonine(HHT) combined with imatinib(IM) on proliferation and apoptosis of K562/G01 cells and its potential mechanism."( [Effect of Homoharringtonine Combined with Imatinib on the K562/G01 Cells and Its Mechanism].
Deng, ZK; Ding, YH; Li, YF; Lu, XY; Shi, YY; Wu, JJ, 2017
)
1.15
"HHT combined with IM can synergistically inhibit proliferation and induce apoptosis of K562/G01 cells by suppressing the p210 expression and its kinase activity."( [Effect of Homoharringtonine Combined with Imatinib on the K562/G01 Cells and Its Mechanism].
Deng, ZK; Ding, YH; Li, YF; Lu, XY; Shi, YY; Wu, JJ, 2017
)
0.84
"To investigate the effect and possible mechanism of low concentration of triptolide (TPL) combined with homoharringtonine (HHT) on the proliferation and apoptosis of KG-1α cells."( [Effects of Triptolide Combined with Homoharringtonine on Proliferation and Apoptosis of KG-1α Cells].
Li, X; Lin, ZX; Liu, JY; Wu, Y; Yuan, XH, 2018
)
0.97
" Westerrn blot was used to detect the expression of Akt signaling pathway related proteins before and after low dose TPL combined with HHT using."( [Effects of Triptolide Combined with Homoharringtonine on Proliferation and Apoptosis of KG-1α Cells].
Li, X; Lin, ZX; Liu, JY; Wu, Y; Yuan, XH, 2018
)
0.75
" CI values also indicated that low concentration TPL combined with HHT possessed highly synergistic effect."( [Effects of Triptolide Combined with Homoharringtonine on Proliferation and Apoptosis of KG-1α Cells].
Li, X; Lin, ZX; Liu, JY; Wu, Y; Yuan, XH, 2018
)
0.75
"Low concentration of TPL combined with HHT can synergistically inhibit KG-1α cell proliferation and induce its apoptosis through the PI3K/Akt signaling pathway and downstream protein."( [Effects of Triptolide Combined with Homoharringtonine on Proliferation and Apoptosis of KG-1α Cells].
Li, X; Lin, ZX; Liu, JY; Wu, Y; Yuan, XH, 2018
)
0.75
"We recommend the "venetoclax + HMAs combined with dose-adjusted CAH/HAG" regimen as an effective treatment for adult R/RAML."( Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports.
Bai, J; Lian, X; Pei, Z; Song, Q; Wang, H; Wang, J; Zhang, B, 2020
)
0.56
"We analyzed the treatment effects of chidamide and decitabine in combination with a HAG (homoharringtonine, cytarabine, G-CSF) priming regimen (CDHAG) in acute myeloid leukemia (AML) patients with TP53 mutation."( Chidamide and Decitabine in Combination with a HAG Priming Regimen for Acute Myeloid Leukemia with TP53 Mutation.
Bai, J; Pei, Z; Song, Q; Wang, H; Wang, J; Wu, H; Zhang, B, 2022
)
0.94
" Furthermore, CCK-8 was used to determine the effects of HCA, alone or in combination with apoptosis inhibitors, necroptosis inhibitors, ferroptosis inhibitors, or autophagy inhibitors, on the proliferation of HL60 and THP1 cells and to screen for possible HCA-mediated death pathways in AML cells."( Homoharringtonine combined with cladribine and aclarubicin (HCA) in acute myeloid leukemia: A new regimen of conventional drugs and its mechanism.
Chen, P; Wang, D; Wang, F; Xie, M; Yang, M, 2022
)
2.16
"To explore the efficacy of tyrosine kinase inhibitor (TKI) combined with decitabine, homoharringtonine, and interferon regimen as maintenance therapy for blast phase chronic myeloid leukemia (CML-BP)."( [Efficacy of Tyrosine Kinase Inhibitor Combined with Decitabine, Homoharringtonine, Interferon in the Maintenance Therapy of Blast Phase Chronic Myeloid Leukemia].
Li, ZY; Song, YP; Zhang, YL; Zhao, HF, 2023
)
1.37
" Kaplan-Meier survival analysis showed that patients in TKI combined with decitabine, homoharringtonine, interferon group had longer event-free survival (7."( [Efficacy of Tyrosine Kinase Inhibitor Combined with Decitabine, Homoharringtonine, Interferon in the Maintenance Therapy of Blast Phase Chronic Myeloid Leukemia].
Li, ZY; Song, YP; Zhang, YL; Zhao, HF, 2023
)
1.37
"The TKI combined with decitabine, homoharringtonine and interferon regimen can significantly prolong the survival of CML-BP patients who obtained the major hematological response compared with TKI combined with conventional chemotherapy regimen."( [Efficacy of Tyrosine Kinase Inhibitor Combined with Decitabine, Homoharringtonine, Interferon in the Maintenance Therapy of Blast Phase Chronic Myeloid Leukemia].
Li, ZY; Song, YP; Zhang, YL; Zhao, HF, 2023
)
1.43

Bioavailability

ExcerptReferenceRelevance
"Omacetaxine is well absorbed after SC administration."( Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors.
Benichou, AC; Craig, A; Gleich, L; Mita, A; Mita, MM; Nanda, N; Nemunaitis, J; Padmanabhan-Iyer, S; Sarantopoulos, J; Stephenson, J, 2013
)
0.39
" Omacetaxine, a semisynthetic form of HHT, with excellent bioavailability by the subcutaneous route, has recently been approved by FDA of the United States for the treatment of CML refractory to tyrosine kinase inhibitors."( Homoharringtonine and omacetaxine for myeloid hematological malignancies.
Lü, S; Wang, J, 2014
)
1.85
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

37 patients with refractory, relapse, hypocellular acute monocytic leukemia and elderly patients with AML-M(5) were treated with GHA-priming therapy (G-CSF, homoharringtonine and low dosage of cytarabine)

ExcerptRelevanceReference
" Dose-response studies found that HHT inhibited colony formation of myeloid cell lines (50% inhibitory dose range, 7 to 12 ng/ml), lymphocytic cell lines (50% inhibitory dose range, 4 to 7 ng/ml), and fresh leukemic cells (50% inhibitory dose range, 2 to 25 ng/ml)."( Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro.
Chen, DL; Koeffler, HP; Shen, ZS; Zhou, JY, 1990
)
0.68
"To prevent the cicatrization of filtering blebs after glaucoma filtering surgery, subconjunctival injections of low dosage homoharringtonine were administered to 22 glaucomatous eyes (20 patients) postoperatively."( [Low dosage of homoharringtonine for prevention of cicatrization after glaucoma filtering surgery].
Li, Z; Shi, F; Shi, H, 1995
)
0.85
" When the high dosage of HHT solution is used, transient elevation of the success rate can be obtained, however the side-effect is also significantly increased."( [Effects of homoharringtonine liposomes and homoharringtonine solution on glaucoma filtration surgery in rabbits].
Chen, K; Jin, W; Li, J; Xu, Y; Yang, G, 1998
)
0.68
" Twenty-four hours after HHT dosing in mice, approximately 29% of the dose was excreted in the urine as HHT and 20% as HHT-acid."( Metabolism of homoharringtonine, a cytotoxic component of the evergreen plant Cephalotaxus harringtonia.
Felix, E; Ho, DH; Newman, RA; Ni, D; Rhea, PR; Vijjeswarapu, M,
)
0.49
" Ph(+)-ANLL patients were infused with HHT over 6-24 hours daily at the doses of 1-2 mg intravenously and Ara-C 30-50 mg daily subcutaneously for 10-14 days; 3 patients with Ph(+)-ALL received HOAP or DOP combination treatment regimens (One cycle consists of HA with the same dosage described above for Ph(+)-ANLL patients for 7 days, daunorubicin at the dose of 40 mg/d intravenously for 3 days, vincristine at the dose of 2 mg/wk for two weeks, and prednisone at the doses of 60-80 mg/d for 14 days)."( [Glivec in combination with HA regimen for treatment of 20 patients with Ph chromosome positive acute leukemia].
Huang, F; Liu, XL; Meng, FY; Song, LL; Xu, B; Zhang, Y; Zheng, WY, 2003
)
0.32
" The dosage of sHHT was escalated by adding one day of treatment every two days."( Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
Andreasson, C; Apperley, JF; Bua, M; Goldman, JM; Kaeda, JS; Marin, D; Olavarria, E; Saunders, SM, 2005
)
0.59
" 37 patients with refractory, relapse, hypocellular acute monocytic leukemia and elderly patients with AML-M(5) were treated with GHA-priming therapy (G-CSF, homoharringtonine and low dosage of cytarabine)."( [Efficiency of GHA priming therapy on patients with acute monocytic leukemia and its mechanism].
Chen, YX; He, AL; Ji, YY; Liu, J; Wang, FX; Wang, JL; Zhang, PY; Zhang, WG; Zhang, WJ; Zhao, XM, 2010
)
0.56
" However, clinically relevant dosing of these adenosine triphosphate-mimetic agents in humans leads to inhibition of numerous tyrosine kinases beyond those touted by drug manufacturers and studied in landmark clinical trials."( Off-Target Effects of BCR-ABL and JAK2 Inhibitors.
Fancher, KM; Green, MR; Newton, MD, 2016
)
0.43
" Compared with low dosage TPL and HHT single-use groups, the cell proliferation and colony formation efficiency were lower, and the cell apoptosis rate was higher in the combined group."( [Effects of Triptolide Combined with Homoharringtonine on Proliferation and Apoptosis of KG-1α Cells].
Li, X; Lin, ZX; Liu, JY; Wu, Y; Yuan, XH, 2018
)
0.75
" However, it requires complicated dosing regimens and is accompanied by increased toxicity."( Co-Delivery of Daunorubicin and Homoharringtonine in Folic Acid Modified-Liposomes for Enhancing Therapeutic Effect on Acute Myeloid Leukemia.
Feng, X; Gao, X; Li, H; Liu, Q; Luo, L; Mao, S; Yang, P; Zhang, D, 2023
)
1.19
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
protein synthesis inhibitorA compound, usually an anti-bacterial agent or a toxin, which inhibits the synthesis of a protein.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
anticoronaviral agentAny antiviral agent which inhibits the activity of coronaviruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
alkaloid ester
tertiary alcoholA tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it.
organic heteropentacyclic compound
enol etherEthers ROR' where R has a double bond adjacent to the oxygen of the ether linkage.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Non-small cell lung cancer05

Protein Targets (34)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency0.09300.00529.466132.9993AID1347411
huntingtin isoform 2Homo sapiens (human)Potency0.15850.000618.41981,122.0200AID1688
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency3.35520.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency0.03760.004611.374133.4983AID624296
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.04780.005612.367736.1254AID624032; AID624044
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency12.58930.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency0.00790.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Interferon betaHomo sapiens (human)Potency0.09300.00339.158239.8107AID1347411
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency2.34300.009610.525035.4813AID1479145; AID1479148
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinBetacoronavirus England 1EC50 (µMol)0.07100.00304.57559.8200AID1804127
Replicase polyprotein 1abBetacoronavirus England 1EC50 (µMol)0.07100.00304.57559.8200AID1804127
Transmembrane protease serine 2Homo sapiens (human)EC50 (µMol)0.07100.00304.51689.8200AID1804127
Procathepsin LHomo sapiens (human)EC50 (µMol)0.07100.00304.48749.8200AID1804127
Replicase polyprotein 1aSevere acute respiratory syndrome-related coronavirusEC50 (µMol)0.07100.00304.61369.8200AID1804127
Replicase polyprotein 1abHuman coronavirus 229EEC50 (µMol)0.07100.00304.61369.8200AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusEC50 (µMol)0.07100.00304.45549.8200AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2EC50 (µMol)0.07100.00304.11059.8200AID1804127
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusEC50 (µMol)0.07100.00304.57559.8200AID1804127
Angiotensin-converting enzyme 2 Homo sapiens (human)EC50 (µMol)0.07100.00304.57559.8200AID1804127
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (76)

Processvia Protein(s)Taxonomy
viral translationTransmembrane protease serine 2Homo sapiens (human)
proteolysisTransmembrane protease serine 2Homo sapiens (human)
protein autoprocessingTransmembrane protease serine 2Homo sapiens (human)
positive regulation of viral entry into host cellTransmembrane protease serine 2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
adaptive immune responseProcathepsin LHomo sapiens (human)
proteolysisProcathepsin LHomo sapiens (human)
protein autoprocessingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host plasma membraneProcathepsin LHomo sapiens (human)
receptor-mediated endocytosis of virus by host cellProcathepsin LHomo sapiens (human)
antigen processing and presentationProcathepsin LHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IIProcathepsin LHomo sapiens (human)
collagen catabolic processProcathepsin LHomo sapiens (human)
zymogen activationProcathepsin LHomo sapiens (human)
enkephalin processingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host endosome membraneProcathepsin LHomo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitmentProcathepsin LHomo sapiens (human)
symbiont entry into host cellProcathepsin LHomo sapiens (human)
antigen processing and presentation of peptide antigenProcathepsin LHomo sapiens (human)
proteolysis involved in protein catabolic processProcathepsin LHomo sapiens (human)
elastin catabolic processProcathepsin LHomo sapiens (human)
macrophage apoptotic processProcathepsin LHomo sapiens (human)
cellular response to thyroid hormone stimulusProcathepsin LHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProcathepsin LHomo sapiens (human)
positive regulation of peptidase activityProcathepsin LHomo sapiens (human)
immune responseProcathepsin LHomo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
negative regulation of signaling receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cytokine productionAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin-mediated drinking behaviorAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme 2 Homo sapiens (human)
tryptophan transportAngiotensin-converting enzyme 2 Homo sapiens (human)
viral life cycleAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of transmembrane transporter activityAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cell population proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of smooth muscle cell proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of inflammatory responseAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of amino acid transportAngiotensin-converting enzyme 2 Homo sapiens (human)
maternal process involved in female pregnancyAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of cardiac muscle contractionAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane fusionAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeAngiotensin-converting enzyme 2 Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme 2 Homo sapiens (human)
entry receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of gap junction assemblyAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cardiac conductionAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of L-proline import across plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityTransmembrane protease serine 2Homo sapiens (human)
protein bindingTransmembrane protease serine 2Homo sapiens (human)
serine-type peptidase activityTransmembrane protease serine 2Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
fibronectin bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityProcathepsin LHomo sapiens (human)
protein bindingProcathepsin LHomo sapiens (human)
collagen bindingProcathepsin LHomo sapiens (human)
cysteine-type peptidase activityProcathepsin LHomo sapiens (human)
histone bindingProcathepsin LHomo sapiens (human)
proteoglycan bindingProcathepsin LHomo sapiens (human)
serpin family protein bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processProcathepsin LHomo sapiens (human)
RNA-dependent RNA polymerase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
virus receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
endopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
metallocarboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
identical protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
extracellular regionTransmembrane protease serine 2Homo sapiens (human)
nucleoplasmTransmembrane protease serine 2Homo sapiens (human)
plasma membraneTransmembrane protease serine 2Homo sapiens (human)
extracellular exosomeTransmembrane protease serine 2Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
extracellular regionProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
nucleusProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
multivesicular bodyProcathepsin LHomo sapiens (human)
Golgi apparatusProcathepsin LHomo sapiens (human)
plasma membraneProcathepsin LHomo sapiens (human)
apical plasma membraneProcathepsin LHomo sapiens (human)
endolysosome lumenProcathepsin LHomo sapiens (human)
chromaffin granuleProcathepsin LHomo sapiens (human)
lysosomal lumenProcathepsin LHomo sapiens (human)
intracellular membrane-bounded organelleProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixProcathepsin LHomo sapiens (human)
extracellular exosomeProcathepsin LHomo sapiens (human)
endocytic vesicle lumenProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
endoplasmic reticulum lumenAngiotensin-converting enzyme 2 Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
ciliumAngiotensin-converting enzyme 2 Homo sapiens (human)
cell surfaceAngiotensin-converting enzyme 2 Homo sapiens (human)
membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
apical plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
endocytic vesicle membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane raftAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (99)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347414qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1634199Inhibition of Nuclear factor erythroid 2-related factor 2 5'-untranslated region guanine-rich DNA sequence in human A549 cells assessed as suppression of GCLC gene expression at 10 nM measured up to 48 hrs by RT-PCR analysis2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Homoharringtonine stabilizes secondary structure of guanine-rich sequence existing in the 5'-untranslated region of Nrf2.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1546853Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
AID400177Antitumor activity against Agrobacterium tumefaciens B6-induced tumor formation at 1.5 ug/disk after 12 days by potato disk assay
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1505078Antiproliferative activity against human HL60 cells after 62 hrs by MTS assay2018Journal of natural products, 01-26, Volume: 81, Issue:1
Sodium-Periodate-Mediated Harringtonine Derivatives and Their Antiproliferative Activity against HL-60 Acute Leukemia Cells.
AID400178Antitumor activity against mouse P388 cells xenografted mouse assessed as increase in life span relative to control
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID400176Antitumor activity against Agrobacterium tumefaciens B6-induced tumor formation at 2.5 ug/disk after 12 days by potato disk assay
AID1634198Inhibition of Nuclear factor erythroid 2-related factor 2 5'-untranslated region guanine-rich DNA sequence in human A549 cells assessed as suppression of AKR1C3 gene expression at 10 nM measured up to 48 hrs by RT-PCR analysis2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Homoharringtonine stabilizes secondary structure of guanine-rich sequence existing in the 5'-untranslated region of Nrf2.
AID387635Cytotoxicity against human A549 cells assessed as reduction of cell growth by SRB method2008Bioorganic & medicinal chemistry letters, Oct-01, Volume: 18, Issue:19
Synthesis of unsymmetrical biphenyls as potent cytotoxic agents.
AID1634206Inhibition of Nrf2 5'-untranslated region guanine-rich DNA sequence in human A549 cells assessed as potentiation of etoposide-induced apoptosis by measuring increase cleaved PARP protein level in at 10 nM after 24 hrs by Western blot analysis2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Homoharringtonine stabilizes secondary structure of guanine-rich sequence existing in the 5'-untranslated region of Nrf2.
AID1634186Inhibition of Nrf2 5'-untranslated region guanine-rich DNA sequence in human A549 cells assessed as potentiation of etoposide-induced cytotoxicity by measuring increase in ROS production at 10 nM after 24 hrs by DCFH-DA based assay2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Homoharringtonine stabilizes secondary structure of guanine-rich sequence existing in the 5'-untranslated region of Nrf2.
AID1546852Cytotoxicity against human A549 cells after 48 hrs by MTT assay
AID1454747Cytotoxicity against human HeLa cells assessed as reduction in protein synthesis at 0.05 uM2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
AID1634193Binding affinity to ssGQPLEX DNA (unknown origin) assessed as dissociation constant by isothermal titration calorimetric method2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Homoharringtonine stabilizes secondary structure of guanine-rich sequence existing in the 5'-untranslated region of Nrf2.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1634202Inhibition of Nuclear factor erythroid 2-related factor 2 5'-untranslated region guanine-rich DNA sequence in human A549 cells harboring ARE-GFP-Luc assessed as reduction in ARE-luciferase activity after 24 hrs by firefly luciferase reporter gene assay2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Homoharringtonine stabilizes secondary structure of guanine-rich sequence existing in the 5'-untranslated region of Nrf2.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1634196Inhibition of Nuclear factor erythroid 2-related factor 2 5'-untranslated region guanine-rich DNA sequence in human A549 cells assessed as reduction in NRF2 mRNA levels at 10 nM after 12 to 36 hrs by RT-PCR analysis2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Homoharringtonine stabilizes secondary structure of guanine-rich sequence existing in the 5'-untranslated region of Nrf2.
AID333842Cytotoxicity against human KB cells
AID1778264Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay2021Journal of natural products, 05-28, Volume: 84, Issue:5
Cytotoxic and Antiangiogenetic Xanthones Inhibiting Tumor Proliferation and Metastasis from
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1634194Stabilization of dsGQPLEX DNA (unknown origin) by circular dichroism method2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Homoharringtonine stabilizes secondary structure of guanine-rich sequence existing in the 5'-untranslated region of Nrf2.
AID1634191Stabilization of ssGQPLEX-delta3,4 DNA lacking third and fourth G blocks (unknown origin) by circular dichroism method2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Homoharringtonine stabilizes secondary structure of guanine-rich sequence existing in the 5'-untranslated region of Nrf2.
AID247402Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
CHMIS-C: a comprehensive herbal medicine information system for cancer.
AID421889In vivo antitumor activity against mouse P388 cells at 0.25 to 1 mg/kg relative to control2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Plant seeds as sources of potential industrial chemicals, pharmaceuticals, and pest control agents.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID52057The concentration of compound required for 50% inhibition of protein synthesis in cell-free lysates1995Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7
Cross-validated R2-guided region selection for comparative molecular field analysis: a simple method to achieve consistent results.
AID400174Antitumor activity against Agrobacterium tumefaciens B6-induced tumor formation at 10 ug/disk after 12 days by potato disk assay
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1634190Stabilization of ssGQPLEX-G/T-1,3 DNA (unknown origin) by circular dichroism method2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Homoharringtonine stabilizes secondary structure of guanine-rich sequence existing in the 5'-untranslated region of Nrf2.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1854078Antiproliferative activity against human K562 cells assessed as cell growth inhibition2022European journal of medicinal chemistry, Aug-05, Volume: 238The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID421890In vivo antitumor activity against mouse L1210 cells at 0.25 to 1 mg/kg relative to control2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Plant seeds as sources of potential industrial chemicals, pharmaceuticals, and pest control agents.
AID1454741Cytotoxicity against human MCF7 cells assessed as reduction in protein synthesis2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1634197Inhibition of Nuclear factor erythroid 2-related factor 2 5'-untranslated region guanine-rich DNA sequence in human A549 cells assessed as suppression of AKR1B10 gene expression at 10 nM measured up to 48 hrs by RT-PCR analysis2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Homoharringtonine stabilizes secondary structure of guanine-rich sequence existing in the 5'-untranslated region of Nrf2.
AID397122Inhibition of HIV1 RT
AID1634203Inhibition of Nuclear factor erythroid 2-related factor 2 5'-untranslated region guanine-rich DNA sequence in human A549 cells assessed as reduction in Nrf2 protein level at 10 nM incubated for 12 to 478 hrs by Western blot analysis2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Homoharringtonine stabilizes secondary structure of guanine-rich sequence existing in the 5'-untranslated region of Nrf2.
AID1879418Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth measured after 68 hrs by MTS assay2022Journal of natural products, 02-25, Volume: 85, Issue:2
Harringtonine Ester Derivatives with Enhanced Antiproliferative Activities against HL-60 and HeLa Cells.
AID1634192Stabilization of ssGQPLEX-delta1,2 DNA lacking first and second G blocks (unknown origin) by circular dichroism method2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Homoharringtonine stabilizes secondary structure of guanine-rich sequence existing in the 5'-untranslated region of Nrf2.
AID387637Cytotoxicity against drug-resistant human KB-VIN cells assessed as reduction of cell growth by SRB method2008Bioorganic & medicinal chemistry letters, Oct-01, Volume: 18, Issue:19
Synthesis of unsymmetrical biphenyls as potent cytotoxic agents.
AID1634187Inhibition of Nrf2 5'-untranslated region guanine-rich DNA sequence in human A549 cells assessed as potentiation of etoposide-induced cytotoxicity by measuring decrease in cell viability at 10 nM after 24 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Homoharringtonine stabilizes secondary structure of guanine-rich sequence existing in the 5'-untranslated region of Nrf2.
AID1879417Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth measured after 68 hrs by MTS assay2022Journal of natural products, 02-25, Volume: 85, Issue:2
Harringtonine Ester Derivatives with Enhanced Antiproliferative Activities against HL-60 and HeLa Cells.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1634205Inhibition of Nrf2 5'-untranslated region guanine-rich DNA sequence in human A549 cells assessed as potentiation of etoposide-induced apoptosis by measuring increase cleaved caspase-3 protein level in at 10 nM after 24 hrs by Western blot analysis2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Homoharringtonine stabilizes secondary structure of guanine-rich sequence existing in the 5'-untranslated region of Nrf2.
AID1634189Stabilization of ssGQPLEX-G/T-2,4 DNA (unknown origin) by circular dichroism method2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Homoharringtonine stabilizes secondary structure of guanine-rich sequence existing in the 5'-untranslated region of Nrf2.
AID1634188Stabilization of ssGQPLEX-G/T-1,2,3,4 DNA by circular dichroism method2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Homoharringtonine stabilizes secondary structure of guanine-rich sequence existing in the 5'-untranslated region of Nrf2.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID387636Cytotoxicity against human KB cells assessed as reduction of cell growth by SRB method2008Bioorganic & medicinal chemistry letters, Oct-01, Volume: 18, Issue:19
Synthesis of unsymmetrical biphenyls as potent cytotoxic agents.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1634201Cytotoxicity against human A549 cells at 1 nM to 10 uM after 24 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Homoharringtonine stabilizes secondary structure of guanine-rich sequence existing in the 5'-untranslated region of Nrf2.
AID1634204Inhibition of Nrf2 5'-untranslated region guanine-rich DNA sequence in human A549 cells assessed as potentiation of etoposide-induced cytotoxicity by measuring increase in apoptosis at 10 nM after 24 hrs by TUNEL assay2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Homoharringtonine stabilizes secondary structure of guanine-rich sequence existing in the 5'-untranslated region of Nrf2.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1634195Stabilization of ssGQPLEX DNA (unknown origin) assessed as increase in the peak of 264 nm wavelength by circular dichroism method2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Homoharringtonine stabilizes secondary structure of guanine-rich sequence existing in the 5'-untranslated region of Nrf2.
AID400175Antitumor activity against Agrobacterium tumefaciens B6-induced tumor formation at 5 ug/disk after 12 days by potato disk assay
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1804127No assay is provided from Article 10.1002/med.21724: \\The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.\\2021Medicinal research reviews, 01, Volume: 41, Issue:1
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (491)

TimeframeStudies, This Drug (%)All Drugs %
pre-199063 (12.83)18.7374
1990's53 (10.79)18.2507
2000's108 (22.00)29.6817
2010's178 (36.25)24.3611
2020's89 (18.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.44 (24.57)
Research Supply Index6.32 (2.92)
Research Growth Index4.87 (4.65)
Search Engine Demand Index57.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials53 (10.58%)5.53%
Reviews47 (9.38%)6.00%
Case Studies15 (2.99%)4.05%
Observational1 (0.20%)0.25%
Other385 (76.85%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (37)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open Label, Single Arm, Single-Center Exploratory Study to Evaluate the Efficacy and Safety of Selinexor and HAAG +/- HMA in Relapsed/Refractory Acute Leukemia (AML) Patients [NCT05805072]20 participants (Anticipated)Interventional2023-05-01Not yet recruiting
A Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection Combined With Chemotherapy in Previously Untreated de Novo Acute Myeloid Leukemia [NCT05941585]90 participants (Anticipated)Interventional2023-07-31Not yet recruiting
A Monocenter Prospective Single Arm Study of Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for Induced Therapy in Adults de Novo Acute Myeloid Leukemia (Non-M3) [NCT05906914]Phase 230 participants (Anticipated)Interventional2023-06-29Recruiting
Concomitant Omacetaxine Mepesuccinate and Azacitidine for Patients With Previously Untreated High Grade Myelodysplastic Syndromes [NCT03564873]Phase 1/Phase 251 participants (Anticipated)Interventional2018-09-17Recruiting
A Phase 2, Randomized, Open Label, Pivotal Study to Evaluate the Efficacy and Safety of HQP1351 in CML CP Patients Who Are Resistant and/or Intolerant to First- and Second-Generation Tyrosine Kinase Inhibitors [NCT04126681]Phase 2144 participants (Actual)Interventional2019-10-21Active, not recruiting
A Phase II Single-arm Open-labeled Study Evaluating Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD [NCT03135054]Phase 240 participants (Anticipated)Interventional2017-10-01Active, not recruiting
an Single Center,Single Arm, Phase 3 Study to Evaluate Efficacy and Safety of PD-1 Inhibitor Combined With Azacytidine and HAG Regimen for Patients With Relapsed or Refractory Acute Myeloid Leukemia. [NCT04722952]Phase 330 participants (Anticipated)Interventional2021-05-01Recruiting
VEN-OM: Phase IB/II Study Of Safety And Efficacy Of Venetoclax When Combined With Escalating Doses Of Omacetaxine In Patients With AML Failing Treatment With Venetoclax-Containing Regimens [NCT04926285]Phase 130 participants (Anticipated)Interventional2022-06-21Recruiting
A Phase II Study of Omacetaxine (OM) and Decitabine (DAC) in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) [NCT02141477]Phase 12 participants (Actual)Interventional2015-05-06Terminated(stopped due to Slow Accrual-2 patients were registered Phase I and none in Phase II)
A Phase II Single-arm Open-labeled Study Evaluating Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD [NCT03170895]Phase 25 participants (Actual)Interventional2017-07-01Completed
A Phase I/II Clinical Trial of Omacetaxine, Azacitidine, and G-CSF for Relapsed and/or Refractory Myelodysplastic Syndromes [NCT02835794]Phase 1/Phase 20 participants (Actual)Interventional2016-08-31Withdrawn(stopped due to Lack of funding to support clinical trial)
A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine. (Omacetaxine) (CGX-635) in the Treatment of Patients With Chronic Myeloid Leukemia. (CML) With the T315I BCR-ABL Gene Mutation [NCT00375219]Phase 2103 participants (Actual)Interventional2006-09-20Completed
A Phase II Open-Label Study of the Intravenous Administration of Homoharringtonine (CGX-635) Combined With the Oral Administration of Gleevec in the Treatment of Patients With Chronic Myeloid Leukemia (CML) in Chronic, Accelerated, and Blast Phase [NCT00114959]Phase 215 participants (Actual)Interventional2005-10-31Terminated(stopped due to Poor enrollment)
A Pharmacokinetic Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors [NCT00675350]Phase 112 participants (Actual)Interventional2008-04-30Completed
A Phase 3, Open Label, Single Arm, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Elderly Newly Diagnosed Acute Myeloid Leukemia Patients. [NCT04083911]Phase 350 participants (Anticipated)Interventional2019-04-01Recruiting
Venetoclax in Combination With Homoharringtonine and Cytarabine in Newly Diagnosed Subjects With Acute Myeloid Leukemia: a Phase 2/3, the Single-arm, Open-label, Monocentric Study [NCT05805098]Phase 2/Phase 360 participants (Anticipated)Interventional2023-03-01Recruiting
Phase I and Pilot Study of Subcutaneous Homoharringtonine in Chronic Myelogenous Leukemia [NCT00006364]Phase 250 participants (Actual)Interventional1999-11-30Completed
PHASE II STUDY OF SIMULTANEOUS HOMOHARRINGTONINE (NSC 141633) AND ALPHA INTERFERON (IFN-A) THERAPY IN CHRONIC MYELOGENOUS LEUKEMIA (CML) [NCT00002574]Phase 287 participants (Actual)Interventional1994-09-30Completed
Venetoclax Combined With Azacitidine Plus Homoharringtonine Versus Venetoclax Combined With Azacitidine for Relapsed/Refractory Acute Myeloid Leukemia:an Open-label, Multicentre, Randomised Phase 3 Trial [NCT05457361]Phase 3162 participants (Anticipated)Interventional2022-03-01Recruiting
A Single-arm Open-label Multicenter Clinical Study of Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia [NCT05726110]Phase 350 participants (Anticipated)Interventional2023-01-29Recruiting
A Phase I/II Open-Label Study Of The Intravenous Administration Of Homoharringtonine (CGX-635) Salvage Therapy For The Treatment Of Refractory Acute Promyelocytic Leukemia [NCT00030355]Phase 1/Phase 20 participants (Actual)InterventionalWithdrawn
Omacetaxine for Consolidation and Maintenance in Patients Age ≥ 55 With AML in First Remission: A Pilot Study [NCT01873495]Phase 27 participants (Actual)Interventional2013-05-31Terminated
An Open-Label Study to Investigate the Pharmacokinetics (Absorption, Distribution, Metabolism, and Excretion) of Omacetaxine Mepesuccinate Following Subcutaneous Administration of [14C]Omacetaxine Mepesuccinate in Patients With Relapsed and/or Refractory [NCT01844869]Phase 16 participants (Actual)Interventional2013-07-31Completed
A Phase II Study of Newly Diagnosed Patients With BCR/ABL (+) Chronic Myelogenous Leukemia Treated With Combined Homoharringtonine (NSC #141633) and Low-Dose Cytarabine [NCT00003694]Phase 260 participants (Actual)Interventional1999-03-31Completed
Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of Secondary Acute Myeloid Leukemia [NCT05513131]Phase 230 participants (Anticipated)Interventional2021-09-30Recruiting
A Phase III Study of Interferon-Refractory Patients With BCR/ABL(+) Chronic Myelogenous Leukemia (CML) Treated With Homoharringtonine (NSC #141633) vs. Hydroxyurea [NCT00004933]Phase 35 participants (Actual)Interventional2000-01-31Terminated(stopped due to Poor accrual)
Phase Ib/II Study of Omacetaxine and Venetoclax for Patients With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 [NCT04874194]Phase 1/Phase 284 participants (Anticipated)Interventional2021-12-17Recruiting
A Phase II Study of Omacetaxine (OM) in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure [NCT02159872]Phase 248 participants (Actual)Interventional2015-05-18Completed
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Alpha Interferon (IFN-A), Low-Dose Cytosine Arabinoside (ARA-C), and Homoharringtonine (HHT) [NCT00003239]Phase 290 participants (Actual)Interventional1998-03-31Completed
A Phase II Study of Omacetaxine (OM) and Low Dose Cytarabine (LDAC) in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) [NCT01272245]Phase 236 participants (Actual)Interventional2011-07-31Completed
AML-02: Study of the Activity and Safety of the Addition of Omacetaxine to the Standard-of-Care Induction Therapy Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients [NCT02440568]Phase 1/Phase 222 participants (Actual)Interventional2015-06-05Terminated
A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine. (Omacetaxine Mepesuccinate; OMA) in the Treatment of Patients With Chronic Myeloid. Leukemia (CML) Who Have Failed or Are Intolerant to Tyrosine Kinase Inhibitor Therapy [NCT00462943]Phase 2100 participants (Actual)Interventional2007-03-07Completed
Efficacy of Concomitant Use of Azacitidine and Homoharringtonine in Children With Juvenile Myelomonocytic Leukemia [NCT04505995]30 participants (Anticipated)Interventional2020-01-01Recruiting
A Phase 3, Open-Label, Multicenter, Randomized Study of SKLB1028 Versus Salvage Chemotherapy in Patients With FLT3-mutated Acute Myeloid Leukemia Refractory to or Relapsed After First-line Treatment(ALIVE) [NCT04716114]Phase 3315 participants (Anticipated)Interventional2021-03-24Recruiting
An Open-Label, Single-Group Clinical Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Mepesuccinate Given Subcutaneously as a Fixed Dose inPatients With Chronic Phase or Accelerated Phase Chronic Myeloid Leukemia Who Have Failed [NCT02078960]Phase 1/Phase 210 participants (Actual)Interventional2014-10-09Terminated(stopped due to Inability to accrue additional sites and enroll an adequate number of subjects.)
OAG and Decitabine for Newly Diagnosed Acute Myeloid Leukemia Patients Greater Than or Equal to 65 Years of Age [NCT02029417]Phase 22 participants (Actual)Interventional2014-07-31Terminated(stopped due to Major revisions needed in study)
Clinical Study of Azacitidine Combined With Homoharringtonie Based Regimens in Acute Myeloid Leukemia [NCT04248595]Phase 2100 participants (Anticipated)Interventional2019-12-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00114959 (1) [back to overview]Number of Participants With Adverse Experiences (AEs)
NCT00375219 (16) [back to overview]Kaplan-Meier Estimates for Duration of Best Cytogenetic Response
NCT00375219 (16) [back to overview]Kaplan-Meier Estimates for Duration of Best Hematologic Response
NCT00375219 (16) [back to overview]Kaplan-Meier Estimates for Overall Survival
NCT00375219 (16) [back to overview]Kaplan-Meier Estimates for Time to Disease Progression
NCT00375219 (16) [back to overview]Kaplan-Meier Estimates for Time to Onset of Best Cytogenetic Response
NCT00375219 (16) [back to overview]Kaplan-Meier Estimates for Time to Onset of Best Hematologic Response
NCT00375219 (16) [back to overview]Number of Treatment Cycles Needed to Achieve Best Cytogenetic Response
NCT00375219 (16) [back to overview]Number of Treatment Cycles Needed to Achieve Best Hematologic Response
NCT00375219 (16) [back to overview]Percentage of Participants Achieving a Major Cytogenetic Response by Subpopulation and Total Population
NCT00375219 (16) [back to overview]Percentage of Participants Achieving an Overall Hematologic Response by Subpopulation and Total Population
NCT00375219 (16) [back to overview]Percentage of Participants With Major Molecular Response (MMR) Representing the Degree of Suppression of BCR-ABL Transcript Levels Using the Housekeeping Gene ABL
NCT00375219 (16) [back to overview]Percentage of Participants With Major Molecular Response (MMR) Representing the Degree of Suppression of BCR-ABL Transcript Levels Using the Housekeeping Gene GUS
NCT00375219 (16) [back to overview]Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Subpopulation and Total
NCT00375219 (16) [back to overview]Percentage of Participants in Each Cytogenetic Response Category Representing the Degree of Suppression of the Philadelphia Chromosome (Ph+)
NCT00375219 (16) [back to overview]Percentage of Participants in Each Hematologic Response Category
NCT00375219 (16) [back to overview]Percentage of Participants With the Largest Percentage Reduction From Baseline of T315I Mutated BCR-ABL
NCT00462943 (17) [back to overview]Kaplan-Meier Estimates for Time to Onset of Best Cytogenetic Response
NCT00462943 (17) [back to overview]Kaplan-Meier Estimates for Time to Onset of Best Hematologic Response
NCT00462943 (17) [back to overview]Number of Treatment Cycles Needed to Achieve Best Cytogenetic Response
NCT00462943 (17) [back to overview]Percentage of Participants Achieving a Major Cytogenetic Response by Subpopulation and Total Population
NCT00462943 (17) [back to overview]Percentage of Participants Achieving an Overall Hematologic Response by Subpopulation and Total Population
NCT00462943 (17) [back to overview]Percentage of Participants With Major Molecular Response (MMR) Representing the Degree of Suppression of BCR-ABL Transcript Levels Using the Housekeeping Gene ABL
NCT00462943 (17) [back to overview]Kaplan-Meier Estimates for Duration of Best Cytogenetic Response
NCT00462943 (17) [back to overview]Percentage of Participants With Major Molecular Response (MMR) Representing the Degree of Suppression of BCR-ABL Transcript Levels Using the Housekeeping Gene GUS
NCT00462943 (17) [back to overview]Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Subpopulation and Total
NCT00462943 (17) [back to overview]Percentage of Participants in Each Cytogenetic Response Category Representing the Degree of Suppression of the Philadelphia Chromosome (Ph+)
NCT00462943 (17) [back to overview]Percentage of Participants in Each Hematologic Response Category
NCT00462943 (17) [back to overview]Percentage of Participants With Extramedullary Disease (EMD) at Baseline Achieving a Clinical Response
NCT00462943 (17) [back to overview]Percentage of Participants With the Largest Percentage Reduction From Baseline of T315I Mutated BCR-ABL
NCT00462943 (17) [back to overview]Number of Treatment Cycles Needed to Achieve Best Hematologic Response
NCT00462943 (17) [back to overview]Kaplan-Meier Estimates for Duration of Best Hematologic Response
NCT00462943 (17) [back to overview]Kaplan-Meier Estimates for Overall Survival
NCT00462943 (17) [back to overview]Kaplan-Meier Estimates for Time to Disease Progression
NCT01272245 (5) [back to overview]Disease-free Survival
NCT01272245 (5) [back to overview]Evaluation of CR Duration
NCT01272245 (5) [back to overview]Induction Mortality
NCT01272245 (5) [back to overview]Overall Survival
NCT01272245 (5) [back to overview]Percentage of Participants With Complete Remission (CR)
NCT02029417 (1) [back to overview]Frequency of Adverse Events, Graded According to NCI CTCAE v4.0
NCT02078960 (13) [back to overview]Apparent Volume of Distribution (V/F) for Omacetaxine
NCT02078960 (13) [back to overview]Area Under the Drug Concentration by Time Curve From Time 0 to Infinity (AUC0-inf) for Omacetaxine
NCT02078960 (13) [back to overview]Area Under the Drug Concentration by Time Curve From Time 0 to the Time of the Last Measurable Drug Concentration (AUC0-t) for Omacetaxine
NCT02078960 (13) [back to overview]Longest Duration of Response At Study Termination
NCT02078960 (13) [back to overview]Maximum Observed Plasma Concentration (Cmax) for Omacetaxine
NCT02078960 (13) [back to overview]Number of Participants Who Achieved a Major Response at Any Time During Treatment
NCT02078960 (13) [back to overview]Number of Participants Who Were Alive and Progression-Free at Study Termination
NCT02078960 (13) [back to overview]Number of Participants Who Were Alive at Study Termination
NCT02078960 (13) [back to overview]Terminal Elimination Half-Life (t1/2) for Omacetaxine
NCT02078960 (13) [back to overview]Time to Maximum Observed Plasma Concentration (Cmax) for Omacetaxine
NCT02078960 (13) [back to overview]Total Oral Clearance (CL/F) for Omacetaxine
NCT02078960 (13) [back to overview]Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT02078960 (13) [back to overview]Number of Participants Who Had a Molecular Response at Any Time During Treatment
NCT02159872 (2) [back to overview]Number of Participants With a Response
NCT02159872 (2) [back to overview]Overall Survival (OS)
NCT02440568 (6) [back to overview]Event Free Survival
NCT02440568 (6) [back to overview]Optimally Tolerated Dose
NCT02440568 (6) [back to overview]Overall Participant Survival
NCT02440568 (6) [back to overview]Progression Free Survival
NCT02440568 (6) [back to overview]Time to Hematologic Recovery
NCT02440568 (6) [back to overview]Toxicity: Describe by the Adverse Events as Assessed by the CTCAE Grading

Number of Participants With Adverse Experiences (AEs)

"Summary of participants who had adverse events (AEs), who discontinued treatment due to the AE, who had serious adverse events (SAEs), and who had SAEs that were related to treatments.~A serious adverse event is one that at any dose of the study drug or at any time during the period of observation:~Results in death;~Is life threatening;~Requires inpatient hospitalization or prolongation of existing hospitalization;~Results in persistent or significant disability/incapacity;~Is a congenital anomaly/birth defect;~Is medically important.~The Investigator assessed each AE for potential causal relationship between the event and study drug. An investigator assessment of possibly, probably or unknown relation is considered related." (NCT00114959)
Timeframe: up to 3 years

Interventionparticipants (Number)
AEsDiscontinued due to AESerious AEsSAEs considered related
Homoharringtonine + Imatinib Mesylate152127

[back to top]

Kaplan-Meier Estimates for Duration of Best Cytogenetic Response

Duration of response is defined as the time from first reported date of cytogenetic response until the earliest date of objective evidence of disease progression, relapse or death. Data was censored at the last examination date for participants with ongoing response or participants who discontinued treatment for reasons other than adverse event, disease progression or death. (NCT00375219)
Timeframe: up to 4 years

Interventionmonths (Median)
CML: Chronic Phase6.64
CML: Accelerated Phase16.35

[back to top]

Kaplan-Meier Estimates for Duration of Best Hematologic Response

Duration of response is defined as the time from first reported date of hematologic response until the earliest date of objective evidence of disease progression, relapse or death. Data was censored at the last examination date for participants with ongoing response or participants who discontinued treatment for reasons other than adverse event, disease progression or death. (NCT00375219)
Timeframe: up to 4 years

Interventionmonths (Median)
CML: Chronic Phase9.08
CML: Accelerated Phase3.59
CML: Blast Phase3.31

[back to top]

Kaplan-Meier Estimates for Overall Survival

Overall survival is defined as the time from the initiation of treatment until death from any cause or the last day of participant contact or evaluation for participants that were lost to follow-up. Participants were censored t the last recorded contract or evaluation when a participant was alive at time of analysis. A quarterly phone survey was conducted to collect survival data for participants who discontinued from the study. (NCT00375219)
Timeframe: up to 4 years

Interventionmonths (Median)
CML: Chronic Phase49.31
CML: Accelerated Phase18.72
CML: Blast Phase3.45
Total Participants21.51

[back to top]

Kaplan-Meier Estimates for Time to Disease Progression

Time to disease progression is defined as the time from the initiation of treatment until the onset date of death, the development of CML accelerated phase or blast phase, or the loss of complete hematologic response or major cytogenetic response, whichever came first. Participants were censored only if they did not have progression or if they discontinued treatment for reasons other than AE, progression or death. (NCT00375219)
Timeframe: up to 4 years

Interventionmonths (Median)
CML: Chronic Phase7.73
CML: Accelerated Phase4.74
CML: Blast Phase2.20
Total Participants5.86

[back to top]

Kaplan-Meier Estimates for Time to Onset of Best Cytogenetic Response

"Time to onset was analyzed using Kaplan-Meier estimates. Participants who did not achieve a response are censored at their last visit day.~Major cytogenetic response includes complete or partial response. Both confirmed and unconfirmed major cytogenetic response is considered meaningful.~Unconfirmed response is based on a single bone marrow cytogenetic evaluation for participants where a confirmatory evaluation is not available.~Complete response shows 0% Philadelphia chromosome positive (Ph+) cells. A partial response shows >0% - 35% Ph+ cells." (NCT00375219)
Timeframe: up to 3 years

Interventionmonths (Median)
CML: Chronic PhaseNA
CML: Accelerated PhaseNA
CML: Blast PhaseNA

[back to top]

Kaplan-Meier Estimates for Time to Onset of Best Hematologic Response

"Time to onset was analyzed using Kaplan-Meier estimates. Participants who did not achieve a response are censored at their last visit day.~Overall hematologic response for chronic phase participants includes confirmed complete hematologic response (CHR). Overall hematologic response for accelerated or blast phase participants includes confirmed complete hematologic response (CHR), no evidence of leukemia (NEL), or return to chronic phase (RCP). Hematologic response must last >= 8 weeks to be considered meaningful." (NCT00375219)
Timeframe: Day 1 up to Month 6

Interventionmonths (Median)
CML: Chronic Phase0.46
CML: Accelerated Phase1.74
CML: Blast PhaseNA

[back to top]

Number of Treatment Cycles Needed to Achieve Best Cytogenetic Response

(NCT00375219)
Timeframe: Day 1 up to 22 months

Interventiontreatment cycles (Median)
CML: Chronic Phase3.0
CML: Accelerated Phase2.5
CML: Blast Phase2.0
Total Participants3.0

[back to top]

Number of Treatment Cycles Needed to Achieve Best Hematologic Response

Induction therapy was administered for 14 consecutive days for each 28 days cycle, for up to 6 cycles. All treatment arms were given omacetaxine mepesuccinate via subcutaneous (SC) administration at 1.25 mg/m^2 twice a day (BID) for the 14 consecutive days. (NCT00375219)
Timeframe: Day 1 up to Month 6

Interventiontreatment cycles (Median)
CML: Chronic Phase1.0
CML: Accelerated Phase1.0
CML: Blast Phase1.0
Total Participants1.0

[back to top]

Percentage of Participants Achieving a Major Cytogenetic Response by Subpopulation and Total Population

"Subpopulations reflect chronic myeloid leukemia (CML) phases at the time of enrollment: chronic, accelerated, and blast phase. Primary endpoints as adjudicated by the Data Monitoring Committee were used for the primary analyses.~Major cytogenetic response includes complete or partial response. Both confirmed and unconfirmed major cytogenetic response is considered meaningful.~Unconfirmed response is based on a single bone marrow cytogenetic evaluation for participants where a confirmatory evaluation is not available.~Complete response shows 0% Philadelphia chromosome positive (Ph+) cells. A partial response shows >0% - 35% Ph+ cells.~Response rates by disease phase were examined relative to an a priori value of 2.5% using a one-sided lower 95% exact binomial confidence limit. If the lower limit from the one-sided lower 95% confidence limit exceeds 2.5%, the observed response rate will have exceeded the minimum threshold required to demonstrate efficacy." (NCT00375219)
Timeframe: Day 1 up to 6 months

Interventionpercentage of participants (Number)
CML: Chronic Phase22.6
CML: Accelerated Phase5.0
CML: Blast Phase0
Total Participants14.6

[back to top]

Percentage of Participants Achieving an Overall Hematologic Response by Subpopulation and Total Population

"Subpopulations reflect chronic myeloid leukemia (CML) phases at the time of enrollment: chronic, accelerated, and blast phase. Primary endpoints as adjudicated by the Data Monitoring Committee were used for the primary analyses.~Overall hematologic response for chronic phase participants includes confirmed complete hematologic response (CHR). Overall hematologic response for accelerated or blast phase participants includes confirmed complete hematologic response (CHR), no evidence of leukemia (NEL), or return to chronic phase (RCP). Hematologic response must last >= 8 weeks to be considered meaningful.~Response rates by disease phase were examined relative to an a priori value of 2.5% using a one-sided lower 95% exact binomial confidence limit. If the lower limit from the one-sided lower 95% confidence limit exceeds 2.5%, the observed response rate will have exceeded the minimum threshold required to demonstrate efficacy." (NCT00375219)
Timeframe: Day 1 up to 6 months

Interventionpercentage of participants (Number)
CML: Chronic Phase77.4
CML: Accelerated Phase55.0
CML: Blast Phase9.5
Total Participants59.2

[back to top]

Percentage of Participants With Major Molecular Response (MMR) Representing the Degree of Suppression of BCR-ABL Transcript Levels Using the Housekeeping Gene ABL

MMR is defined as a ratio of BCR-ABL/standard gene of less than 0.1% according to the international scale. BCR-ABL is a fusion gene of the breakpoint cluster region [BCR] gene and Abelson proto-oncogene [ABL] genes). This analysis used the standard gene ABL. Analysis was performed by quantitative reverse transcription polymerase chain reaction (qRT-PCR) of peripheral blood. (NCT00375219)
Timeframe: Day 1 up to Month 6

Interventionpercentage of participants (Number)
CML: Chronic Phase19.2
CML: Accelerated Phase15.4
CML: Blast Phase0
Total Participants16.4

[back to top]

Percentage of Participants With Major Molecular Response (MMR) Representing the Degree of Suppression of BCR-ABL Transcript Levels Using the Housekeeping Gene GUS

MMR is defined as a ratio of BCR-ABL/standard gene of less than 0.1% according to the international scale. BCR-ABL is a fusion gene of the breakpoint cluster region [BCR] gene and Abelson proto-oncogene [ABL] genes). This analysis used the standard gene GUS. Analysis was performed by quantitative reverse transcription polymerase chain reaction (qRT-PCR) of peripheral blood. (NCT00375219)
Timeframe: Day 1 up to Month 6

Interventionpercentage of participants (Number)
CML: Chronic Phase8.1
CML: Accelerated Phase12.5
CML: Blast Phase0
Total Participants8.2

[back to top]

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Subpopulation and Total

"TEAE are any untoward events that were newly occurring or worsening from Baseline.~Treatment related toxicity was considered by the investigator to be unrelated, possibly, probably or unknown related to study drug.~Severity was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 on the following scale: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death.~A serious adverse event (SAE) is any untoward medical occurrence that is fatal or life-threatening; results in persistent or significant disability or incapacity; requires or prolongs in-patient hospitalization; is a congenital anomaly/birth defect in the offspring of a patient; and conditions not included in the above that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.~A participant is only counted once in each category (at worst severity or strongest relationship)." (NCT00375219)
Timeframe: up to 3 years

,,,
Interventionparticipants (Number)
>=1 TEAE>= 1 SAEWorst severity: Grade 1Worst severity: Grade 2Worst severity: Grade 3Worst severity: Grade 4Worst severity: Grade 5Relation to drug: UnrelatedRelation to drug: PossiblyRelation to drug: ProbablyRelation to drug: UnknownWith hematologic toxicityDiscontinued treatment due to AEDeaths during study or follow-upDeaths during study (outcome of SAE)
CML: Accelerated Phase201212494331311310144
CML: Blast Phase21190144123513013111912
CML: Chronic Phase6136069379165405518319
Total Participants102671917502571480181396425

[back to top]

Percentage of Participants in Each Cytogenetic Response Category Representing the Degree of Suppression of the Philadelphia Chromosome (Ph+)

"Cytogenetic response categories:~Complete: 0% Ph+ cells~Partial: >0%-35% Ph+ cells~Minor: >35%-65% Ph+ cells~Minimal: >65%-95% Ph+ cells~No Response: >95% Ph+ cells~Unevaluable: <20 metaphases were examined and/or response could not be assigned" (NCT00375219)
Timeframe: Day 1 up to Month 9

,,,
Interventionpercentage of participants (Number)
CompletePartialMinorMinimalNo ResponseUnevaluable
CML: Accelerated Phase5.0005.030.060.0
CML: Blast Phase0009.538.152.4
CML: Chronic Phase16.16.54.816.137.119.4
Total Participants10.73.92.912.635.934.0

[back to top]

Percentage of Participants in Each Hematologic Response Category

"Complete Response (CHR)~Chronic phase must last at least 8 weeks: WBC <10*10^9/liter, platelets <450*10^9/liter, myelocytes + metamyelocytes <5% in blood, no blasts or promyelocytes in blood, <20% basophils in peripheral blood, no extramedullary involvement.~Accelerated and Blast phase must last at least 4 weeks: absolute neutrophil count 1.5*10^9/liter, platelets 100*10^9/liter, no blood blasts, bone marrow blasts <5%, no extramedullary disease.~Partial Response - CHR plus one or more of the following:~Persistence of splenomegaly with a reduction of ≥50% from pre-treatment~Platelets > 450*10^9/L~Presence of immature cells in the peripheral blood~5% to 25% blasts in the bone marrow~If extra-medullary disease pre-treatment, reduction by ≥50% Hematologic Improvement - CHR, except allowing persistent thrombocytopenia (<100*10^9/L), and a few immature cells No evidence of leukemia: Morphologic leukemia-free state, defined as <5% bone marrow blasts." (NCT00375219)
Timeframe: Day 1 up to Month 6

,,,
Interventionpercentage of participants (Number)
Complete responsePartial responseHematologic improvementReturn to chronic phaseNo evidence of leukemiaNo responseUnevaluable
CML: Accelerated Phase45.0005.05.025.020.0
CML: Blast Phase4.804.84.8081.04.8
CML: Chronic Phase77.400NANA19.43.2
Total Participants56.301.01.91.033.06.8

[back to top]

Percentage of Participants With the Largest Percentage Reduction From Baseline of T315I Mutated BCR-ABL

Summarization is based on the best of the individual response assessments. Not assessable indicates that the participant either had no baseline assessment or the % mutation could not be determined in the post-baseline assessment(s). (NCT00375219)
Timeframe: Day 1 up to Month 9

,,,
Interventionpercentage of participants (Number)
100% reduction75-99% reduction50-74% reduction25-49% reduction1-24% reduction0% reductionNot assessable
CML: Accelerated Phase00015.438.515.430.8
CML: Blast Phase025.012.5012.525.025.0
CML: Chronic Phase6.04.014.018.08.014.036.0
Total Participants4.25.611.315.514.115.533.8

[back to top]

Kaplan-Meier Estimates for Time to Onset of Best Cytogenetic Response

"Time to onset was analyzed using Kaplan-Meier estimates. Participants who did not achieve a response are censored at their last visit day.~Major cytogenetic response includes complete or partial response. Both confirmed and unconfirmed major cytogenetic response is considered meaningful. Unconfirmed response is based on a single bone marrow cytogenetic evaluation for participants where a confirmatory evaluation is not available.~Complete response shows 0% Philadelphia chromosome positive (Ph+) cells. A partial response shows >0% - 35% Ph+ cells." (NCT00462943)
Timeframe: Day 1 up to Month 9

Interventionmonths (Median)
CML: Chronic PhaseNA
CML: Accelerated PhaseNA
CML: Blast PhaseNA

[back to top]

Kaplan-Meier Estimates for Time to Onset of Best Hematologic Response

"Time to onset was analyzed using Kaplan-Meier estimates. Participants who did not achieve a response are censored at their last visit day.~Overall hematologic response for chronic phase participants includes confirmed complete hematologic response (CHR). Overall hematologic response for accelerated or blast phase participants includes confirmed complete hematologic response (CHR), no evidence of leukemia (NEL), or return to chronic phase (RCP). Hematologic response must last >= 8 weeks to be considered meaningful." (NCT00462943)
Timeframe: Day 1 up to Month 6

Interventionmonths (Median)
CML: Chronic Phase1.38
CML: Accelerated PhaseNA
CML: Blast PhaseNA
Total Participants5.03

[back to top]

Number of Treatment Cycles Needed to Achieve Best Cytogenetic Response

(NCT00462943)
Timeframe: Day 1 up to Month 9

Interventiontreatment cycles (Median)
CML: Chronic Phase2.0
CML: Accelerated Phase1.5
CML: Blast Phase1.0
Total Participants2.0

[back to top]

Percentage of Participants Achieving a Major Cytogenetic Response by Subpopulation and Total Population

"Subpopulations reflect chronic myeloid leukemia (CML) phases at the time of enrollment: chronic, accelerated, and blast phase. Primary endpoints as adjudicated by the Data Monitoring Committee were used for the primary analyses.~Major cytogenetic response includes complete or partial response. Both confirmed and unconfirmed major cytogenetic response is considered meaningful. Unconfirmed response is based on a single bone marrow cytogenetic evaluation for participants where a confirmatory evaluation is not available.~Complete response shows 0% Philadelphia chromosome positive (Ph+) cells. A partial response shows >0% - 35% Ph+ cells.~Response rates by disease phase were examined relative to an a priori value of 2.5% using a one-sided lower 95% exact binomial confidence limit. If the lower limit from the one-sided lower 95% confidence limit exceeds 2.5%, the observed response rate will have exceeded the minimum threshold required to demonstrate efficacy." (NCT00462943)
Timeframe: Day 1 up to 9 months

Interventionpercentage of participants (Number)
CML: Chronic Phase21.7
CML: Accelerated Phase3.2
CML: Blast Phase0
Total Participants11

[back to top]

Percentage of Participants Achieving an Overall Hematologic Response by Subpopulation and Total Population

"Subpopulations reflect chronic myeloid leukemia (CML) phases at the time of enrollment: chronic, accelerated, and blast phase. Primary endpoints as adjudicated by the Data Monitoring Committee were used for the primary analyses.~Overall hematologic response for chronic phase participants includes confirmed complete hematologic response (CHR). Overall hematologic response for accelerated or blast phase participants includes confirmed complete hematologic response (CHR), no evidence of leukemia (NEL), or return to chronic phase (RCP). Hematologic response must last >= 8 weeks to be considered meaningful.~Response rates by disease phase were examined relative to an a priori value of 2.5% using a one-sided lower 95% exact binomial confidence limit. If the lower limit from the one-sided lower 95% confidence limit exceeds 2.5%, the observed response rate will have exceeded the minimum threshold required to demonstrate efficacy." (NCT00462943)
Timeframe: Day 1 up to 6 months

Interventionpercentage of participants (Number)
CML: Chronic Phase67.4
CML: Accelerated Phase25.8
CML: Blast Phase8.7
Total Participants41.0

[back to top]

Percentage of Participants With Major Molecular Response (MMR) Representing the Degree of Suppression of BCR-ABL Transcript Levels Using the Housekeeping Gene ABL

MMR is defined as a ratio of BCR-ABL/standard gene of less than 0.1% according to the international scale. BCR-ABL is a fusion gene of the breakpoint cluster region [BCR] gene and Abelson proto-oncogene [ABL] genes). This analysis used the standard gene ABL. Analysis was performed by quantitative reverse transcription polymerase chain reaction (qRT-PCR) of peripheral blood. (NCT00462943)
Timeframe: Day 1 up to Month 6

Interventionpercentage of participants (Number)
CML: Chronic Phase10.5
CML: Accelerated Phase4.3
CML: Blast Phase0
Total Participants6.9

[back to top]

Kaplan-Meier Estimates for Duration of Best Cytogenetic Response

Duration of response is defined as the time from first reported date of cytogenetic response until the earliest date of objective evidence of disease progression, relapse or death. Data was censored at the last examination date for participants with ongoing response or participants who discontinued treatment for reasons other than adverse event, disease progression or death. (NCT00462943)
Timeframe: up to four years

Interventionmonths (Median)
CML: Chronic Phase6.01
CML: Accelerated Phase0.07

[back to top]

Percentage of Participants With Major Molecular Response (MMR) Representing the Degree of Suppression of BCR-ABL Transcript Levels Using the Housekeeping Gene GUS

MMR is defined as a ratio of BCR-ABL/standard gene of less than 0.1% according to the international scale. BCR-ABL is a fusion gene of the breakpoint cluster region [BCR] gene and Abelson proto-oncogene [ABL] genes). This analysis used the standard gene GUS. Analysis was performed by quantitative reverse transcription polymerase chain reaction (qRT-PCR) of peripheral blood. (NCT00462943)
Timeframe: Day 1 up to Month 6

Interventionpercentage of participants (Number)
CML: Chronic Phase13.6
CML: Accelerated Phase0
CML: Blast Phase0
Total Participants6.8

[back to top]

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Subpopulation and Total

"TEAE are any untoward events that were newly occurring or worsening from Baseline.~Treatment related toxicity was considered by the investigator to be unrelated, possibly, probably or unknown related to study drug. Severity was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 on the following scale: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death. A serious adverse event (SAE) is any untoward medical occurrence that is fatal or life-threatening; results in persistent or significant disability or incapacity; requires or prolongs in-patient hospitalization; is a congenital anomaly/birth defect in the offspring of a patient; and conditions not included in the above that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.~A participant is only counted once in each category (at worst severity or strongest relationship)." (NCT00462943)
Timeframe: up to 4 years

,,,
Interventionparticipants (Number)
>=1 TEAE>= 1 SAEWorst severity: Grade 1Worst severity: Grade 2Worst severity: Grade 3Worst severity: Grade 4Worst severity: Grade 5Relation to drug: UnrelatedRelation to drug: PossiblyRelation to drug: ProbablyRelation to drug: UnknownWith hematologic toxicityDiscontinued treatment due to AEDeaths during study or follow-upDeaths during study (outcome of SAE)
CML: Accelerated Phase31190461564111422211256
CML: Blast Phase231802461177811362111
CML: Chronic Phase46261418176453613610356
Total Participants10063110283823152358471277123

[back to top]

Percentage of Participants in Each Cytogenetic Response Category Representing the Degree of Suppression of the Philadelphia Chromosome (Ph+)

"Cytogenetic response categories:~Complete: 0% Ph+ cells~Partial: >0%-35% Ph+ cells~Minor: >35%-65% Ph+ cells~Minimal: >65%-95% Ph+ cells~No Response: >95% Ph+ cells~Unevaluable: <20 metaphases were examined and/or response could not be assigned" (NCT00462943)
Timeframe: Day 1 up to Month 9

,,,
Interventionpercentage of participants (Number)
CompletePartialMinorMinimalNo ResponseUnevaluable
CML: Accelerated Phase03.29.76.561.319.4
CML: Blast Phase0004.330.465.2
CML: Chronic Phase4.317.48.76.539.123.9
Total Participants2.09.07.06.044.032.0

[back to top]

Percentage of Participants in Each Hematologic Response Category

"Complete Response (CHR)~Chronic phase must last at least 8 weeks: WBC <10*10^9/liter, platelets <450*10^9/liter, myelocytes + metamyelocytes <5% in blood, no blasts or promyelocytes in blood, <20% basophils in peripheral blood, no extramedullary involvement.~Accelerated and Blast phase must last at least 4 weeks: absolute neutrophil count 1.5*10^9/liter, platelets 100*10^9/liter, no blood blasts, bone marrow blasts <5%, no extramedullary disease.~Partial Response - CHR plus one or more of the following:~Persistence of splenomegaly with a reduction of ≥50% from pre-treatment~Platelets > 450*10^9/L~Presence of immature cells in the peripheral blood~5% to 25% blasts in the bone marrow~If extra-medullary disease pre-treatment, reduction by ≥50% Hematologic Improvement - CHR, except allowing persistent thrombocytopenia (<100*10^9/L), and a few immature cells No evidence of leukemia: Morphologic leukemia-free state, defined as <5% bone marrow blasts." (NCT00462943)
Timeframe: Day 1 up to Month 6

,,,
Interventionpercentage of participants (Number)
Complete responsePartial responseHematologic improvementReturn to chronic phaseNo evidence of leukemiaNo responseUnevaluable
CML: Accelerated Phase19.43.29.76.5058.13.2
CML: Blast Phase8.704.30078.38.7
CML: Chronic Phase67.400NANA21.710.9
Total Participants39.01.04.02.0046.08.0

[back to top]

Percentage of Participants With Extramedullary Disease (EMD) at Baseline Achieving a Clinical Response

"Clinical response was defined by disease phase and based on evaluations by the independent Data Monitoring Committee (DMC).~Chronic Phase subgroup: achieving a complete hematologic response and/or major cytogenetic response (complete cytogenetic response or partial cytogenetic response, confirmed or unconfirmed).~Accelerated Phase and Blast Phase subgroups: achieving complete hematologic response, no evidence of leukemia, return to chronic phase, and/or major cytogenetic response (complete cytogenetic response or partial cytogenetic response, confirmed or unconfirmed)." (NCT00462943)
Timeframe: Day 1 up to Month 9

Interventionpercentage of participants (Number)
Clinical responseUnevaluable
CML: Blast Phase050

[back to top]

Percentage of Participants With the Largest Percentage Reduction From Baseline of T315I Mutated BCR-ABL

Summarization is based on the best of the individual response assessments. Not assessable indicates that the participant either had no baseline assessment or the % mutation could not be determined in the post-baseline assessment(s). (NCT00462943)
Timeframe: Day 1 up to Month 9

,,,
Interventionpercentage of participants (Number)
100% reduction75-99% reduction50-74% reduction25-49% reduction1-24% reduction0% reductionNot assessable
CML: Accelerated Phase0000091.38.7
CML: Blast Phase0009.1063.327.3
CML: Chronic Phase0000078.921.1
Total Participants0001.4080.618.1

[back to top]

Number of Treatment Cycles Needed to Achieve Best Hematologic Response

Induction therapy was administered for 14 consecutive days for each 28 days cycle, for up to 6 cycles. All treatment arms were given omacetaxine mepesuccinate via subcutaneous (SC) administration at 1.25 mg/m^2 twice a day (BID) for the 14 consecutive days. (NCT00462943)
Timeframe: Day 1 up to Month 6

Interventiontreatment cycles (Median)
CML: Chronic Phase1.0
CML: Accelerated Phase2.0
CML: Blast Phase2.0
Total Participants1.0

[back to top]

Kaplan-Meier Estimates for Duration of Best Hematologic Response

Duration of response is defined as the time from first reported date of hematologic response until the earliest date of objective evidence of disease progression, relapse or death. Data was censored at the last examination date for participants with ongoing response or participants who discontinued treatment for reasons other than adverse event, disease progression or death. (NCT00462943)
Timeframe: up to four years

Interventionmonths (Median)
CML: Chronic Phase7.01
CML: Accelerated Phase5.47
CML: Blast Phase2.67

[back to top]

Kaplan-Meier Estimates for Overall Survival

Overall survival is defined as the time from the initiation of treatment until death from any cause or the last day of participant contact or evaluation for participants that were lost to follow-up. Participants were censored t the last recorded contract or evaluation when a participant was alive at time of analysis. A quarterly phone survey was conducted to collect survival data for participants who discontinued from the study. (NCT00462943)
Timeframe: up to 4 years

Interventionmonths (Median)
CML: Chronic Phase33.91
CML: Accelerated Phase17.27
CML: Blast Phase3.52
Total Participants17.27

[back to top]

Kaplan-Meier Estimates for Time to Disease Progression

Time to disease progression is defined as the time from the initiation of treatment until the onset date of death, the development of CML accelerated phase or blast phase, or the loss of complete hematologic response or major cytogenetic response, whichever came first. Participants were censored only if they did not have progression or if they discontinued treatment for reasons other than AE, progression or death. (NCT00462943)
Timeframe: up to 4 years

Interventionmonths (Median)
CML: Chronic Phase7.50
CML: Accelerated Phase4.84
CML: Blast Phase2.04
Total Participants4.38

[back to top]

Disease-free Survival

Time from date of treatment start until the date of first objective documentation of disease-relapse. (NCT01272245)
Timeframe: Up to 5 years after completion of active treatment and while on study. Participants may receive up to 24 courses of study medication.

InterventionMonths (Median)
Omacetaxine and Cytarabine3.1

[back to top]

Evaluation of CR Duration

The date of Complete Response to the date of loss of response or last follow-up. (NCT01272245)
Timeframe: Up to 5 years after completion of active treatment and while on study. Participants may receive up to 24 courses of study medication.

InterventionMonths (Median)
Omacetaxine and Cytarabine10.6

[back to top]

Induction Mortality

Death within 8 weeks from the start of treatment. (NCT01272245)
Timeframe: Up to 1 year

InterventionParticipants (Count of Participants)
Omacetaxine and Cytarabine4

[back to top]

Overall Survival

Time from date of treatment start until date of death due to any cause (NCT01272245)
Timeframe: Up to 5 years after completion of active treatment and while on study. Participants may receive up to 24 courses of study medication.

InterventionMonths (Median)
Omacetaxine and Cytarabine8.1

[back to top]

Percentage of Participants With Complete Remission (CR)

Complete response (CR) defined as: Peripheral blood counts, no circulating blasts, neutrophil count ≥ 1.0 ×109/L, platelet count ≥ 100 ×109/L, bone marrow aspirate and biopsy, ≤5% blasts, no detectable auer rods, no extramedulary leukemia (NCT01272245)
Timeframe: Up to 4 months

Interventionpercentage of participants (Number)
Omacetaxine and Cytarabine44

[back to top]

Frequency of Adverse Events, Graded According to NCI CTCAE v4.0

Maximum grade per participant of any AE. (NCT02029417)
Timeframe: Up to 30 days after last dose of study drugs

Interventionparticipants (Number)
Grade 1Grade 2Grade 3Grade 4
Treatment (Cytarabine, Omacetaxine Mepesuccinate, Decitabine)0002

[back to top]

Apparent Volume of Distribution (V/F) for Omacetaxine

Nominal PK sampling times were used. (NCT02078960)
Timeframe: Cycle 1 - Day 1 (predose, 15, 30, 45 minutes, 1, 2, 4, 8, 24, 48, 72 hours post-dose) Day 10 (predose, 2 samples postdose), Day 13 (predose) Cycles 2+3 - Day 1 (2 samples postdose), Days 10 and 17 (1 sample predose)

InterventionL (Mean)
Total Omacetaxine344.9

[back to top]

Area Under the Drug Concentration by Time Curve From Time 0 to Infinity (AUC0-inf) for Omacetaxine

Nominal PK sampling times were used. (NCT02078960)
Timeframe: Cycle 1 - Day 1 (predose, 15, 30, 45 minutes, 1, 2, 4, 8, 24, 48, 72 hours post-dose) Day 10 (predose, 2 samples postdose), Day 13 (predose) Cycles 2+3 - Day 1 (2 samples postdose), Days 10 and 17 (1 sample predose)

Interventionng*hr/mL (Mean)
Total Omacetaxine154.8

[back to top]

Area Under the Drug Concentration by Time Curve From Time 0 to the Time of the Last Measurable Drug Concentration (AUC0-t) for Omacetaxine

Nominal PK sampling times were used. (NCT02078960)
Timeframe: Cycle 1 - Day 1 (predose, 15, 30, 45 minutes, 1, 2, 4, 8, 24, 48, 72 hours post-dose) Day 10 (predose, 2 samples postdose), Day 13 (predose) Cycles 2+3 - Day 1 (2 samples postdose), Days 10 and 17 (1 sample predose)

Interventionng*hr/mL (Mean)
Total Omacetaxine150.2

[back to top]

Longest Duration of Response At Study Termination

Duration of response was defined for responders as the time interval from the first reported date of a major cytogenetic response (MCyR) or a major hematologic response (MaHR) to the earliest date of objective evidence of disease progression (ie, development of accelerated-phase CML), relapse (ie, loss of complete hematologic or major cytogenetic response), or death. Kaplan-Meier estimates for duration of response were not performed due the small enrollment population and early termination of the study. What is reported is the longest duration of response observed prior to disease progression, death, lost to follow-up or study termination. (NCT02078960)
Timeframe: Day 1 to Day 541 (longest progression/survival follow-up)

Interventiondays (Number)
All Enrolled Participants316

[back to top]

Maximum Observed Plasma Concentration (Cmax) for Omacetaxine

Maximum observed plasma drug concentration (Cmax) by inspection (without interpolation). Nominal PK sampling times were used. (NCT02078960)
Timeframe: Cycle 1 - Day 1 (predose, 15, 30, 45 minutes, 1, 2, 4, 8, 24, 48, 72 hours post-dose) Day 10 (predose, 2 samples postdose), Day 13 (predose) Cycles 2+3 - Day 1 (2 samples postdose), Days 10 and 17 (1 sample predose)

Interventionng/mL (Mean)
Total Omacetaxine23.88

[back to top]

Number of Participants Who Achieved a Major Response at Any Time During Treatment

"The Independent Data Monitoring Committee assessments are summarized. Major response for participants with chronic phase CML was a major cytogenetic response (MCyR) defined as a complete cytogenetic response with no Ph+ metaphases, or a partial cytogenetic response with up to 35% Ph+ metaphases. Note that a complete hematologic response was not considered a major response.~Major response for participants with accelerated phase CML was a major hematologic response (MaHR) defined as a complete hematologic response or no evidence of leukemia, and/or a major cytogenic response (MCyR)." (NCT02078960)
Timeframe: Day 1 up to Month 15 (longest treatment duration)

InterventionParticipants (Count of Participants)
Cohort 10
Cohort 21
Cohort 32

[back to top]

Number of Participants Who Were Alive and Progression-Free at Study Termination

Progression-free survival was defined as the time interval from the date of first dose to the date of the earliest objective evidence of disease progression (ie, development of accelerated-phase CML), relapse (ie, loss of complete hematologic or major cytogenetic response), or death. Kaplan-Meier estimates for time for progression-free survival were not performed due the small enrollment population and early termination of the study. What is reported is the number of participants who were alive and progression-free at the time of study termination. (NCT02078960)
Timeframe: Day 1 to Day 541 (longest progression/survival follow-up)

InterventionParticipants (Count of Participants)
All Enrolled Participants4

[back to top]

Number of Participants Who Were Alive at Study Termination

Overall survival was defined as the time interval from the date of the first dose to the date of death from any cause. Kaplan-Meier time estimates for overall survival were not performed due to the small enrollment population and early termination of the study. What is reported is the number of participants who were alive at the time of study termination. (NCT02078960)
Timeframe: Day 1 to Day 541 (longest progression/survival follow-up)

InterventionParticipants (Count of Participants)
All Enrolled Participants7

[back to top]

Terminal Elimination Half-Life (t1/2) for Omacetaxine

Nominal PK sampling times were used. (NCT02078960)
Timeframe: Cycle 1 - Day 1 (predose, 15, 30, 45 minutes, 1, 2, 4, 8, 24, 48, 72 hours post-dose) Day 10 (predose, 2 samples postdose), Day 13 (predose) Cycles 2+3 - Day 1 (2 samples postdose), Days 10 and 17 (1 sample predose)

Interventionhour (Mean)
Total Omacetaxine13.3

[back to top]

Time to Maximum Observed Plasma Concentration (Cmax) for Omacetaxine

Time to maximum observed plasma drug concentration (Cmax) by inspection (without interpolation). Nominal PK sampling times were used. (NCT02078960)
Timeframe: Cycle 1 - Day 1 (predose, 15, 30, 45 minutes, 1, 2, 4, 8, 24, 48, 72 hours post-dose) Day 10 (predose, 2 samples postdose), Day 13 (predose) Cycles 2+3 - Day 1 (2 samples postdose), Days 10 and 17 (1 sample predose)

Interventionhour (Median)
Total Omacetaxine0.25

[back to top]

Total Oral Clearance (CL/F) for Omacetaxine

Nominal PK sampling times were used. (NCT02078960)
Timeframe: Cycle 1 - Day 1 (predose, 15, 30, 45 minutes, 1, 2, 4, 8, 24, 48, 72 hours post-dose) Day 10 (predose, 2 samples postdose), Day 13 (predose) Cycles 2+3 - Day 1 (2 samples postdose), Days 10 and 17 (1 sample predose)

InterventionL/hour (Mean)
Total Omacetaxine18.1

[back to top]

Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event is any untoward medical occurrence in a patient administered a pharmaceutical product, regardless of whether it has a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is an AE that that began or worsened after treatment with study drug. Severity rating of 3=Severe or medically significant but not immediately life-threatening 4=Life-threatening consequences and 5=Death. Relation to study drug is determined by the investigator. A serious adverse event (SAE) includes death, a life-threatening AE, hospitalization, persistent or significant disability or incapacity, a congenital anomaly/birth defect, or any important medical event requiring immediate intervention to prevent one of the outcomes above. (NCT02078960)
Timeframe: Day 1 up to Month 15

,,
InterventionParticipants (Count of Participants)
Any TEAETEAE of Severity Grade 3TEAE of Severity Grade 4TEAE of Severity Grade 5Treatment-related TEAEDeathsSerious AEWithdrawn from treatment due to a TEAE
Cohort 120112221
Cohort 243104020
Cohort 340314140

[back to top]

Number of Participants Who Had a Molecular Response at Any Time During Treatment

Molecular response was defined by the decrease in the amount of BCR-ABL (an abnormality of chromosome 22) messenger ribonucleic acid (mRNA) measured by reverse transcriptase polymerase chain reaction (RT-PCR) or by the actual percentage of BCR-ABL mRNA transcripts (ratio of BCR-ABL transcript numbers to the number of control gene transcripts). (NCT02078960)
Timeframe: Day 1 up to Month 15

InterventionParticipants (Count of Participants)
All Enrolled Participants1

[back to top]

Number of Participants With a Response

Response is Complete Response (CR) + Partial Response (PR) + Hematologic Improvement (HI). CR is the normalization of the peripheral blood and bone marrow with /= (1.0x10^9/L, and a platelet count >/= 100x10^9/L). PR is the same as CR except for the presence of 6-15% marrow blasts, or 50% reduction if <15% at start of treatment. HI meets all of the criteria for CR except for platelet recovery to >/=100x10^9L. (NCT02159872)
Timeframe: Up to 2 years

InterventionParticipants (Count of Participants)
Omacetaxine16

[back to top]

Overall Survival (OS)

Overall survival defined as the time from treatment start to the time of death. Overall survival continuously monitored using the Bayesian method. (NCT02159872)
Timeframe: Up to 2.5 Years

InterventionMonths (Median)
Omacetaxine7.5

[back to top]

Event Free Survival

Observed length of time (days) after which patients remained free of recurrence or death. (NCT02440568)
Timeframe: 6 months

InterventionDays (Median)
Patients With Newly Diagnosed AML, Cohort 166
Patients With Newly Diagnosed AML, Cohort 290.5
Patients With Newly Diagnosed AML, Cohort 365.5
Patients With Newly Diagnosed AML, Cohort 433

[back to top]

Optimally Tolerated Dose

"The primary endpoint is determination of the optimally active and safe dose (OD) of Omacetaxine when added to the standard-of-care induction chemotherapy for AML and estimation of the efficacy and response rate.~OD will be defined as a dose level at which fewer than 30% of patients experience hematologic toxicity and greater than 50% of patients achieve a CR (50% is an accepted CR rate in AML when using a single induction)." (NCT02440568)
Timeframe: Within 50 days (duration of hematologic recovery)

InterventionParticipants treated with OD (Number)
Patients With Newly Diagnosed AML, Cohort 10
Patients With Newly Diagnosed AML, Cohort 20
Patients With Newly Diagnosed AML, Cohort 310
Patients With Newly Diagnosed AML, Cohort 40

[back to top]

Overall Participant Survival

Observed overall survival among participants (days) (NCT02440568)
Timeframe: 3 years

InterventionDays (Median)
Patients With Newly Diagnosed AML, Cohort 1726
Patients With Newly Diagnosed AML, Cohort 2162.5
Patients With Newly Diagnosed AML, Cohort 3792.5
Patients With Newly Diagnosed AML, Cohort 433

[back to top]

Progression Free Survival

Among the participants who achieved CR,CRi, progression free survival in number of days, i.e. the number of days participants who achieved CR/CRi remained alive and in a remission. (NCT02440568)
Timeframe: 3 years

InterventionDays (Median)
Patients With Newly Diagnosed AML, Cohort 1852.5
Patients With Newly Diagnosed AML, Cohort 2100
Patients With Newly Diagnosed AML, Cohort 31241.5
Patients With Newly Diagnosed AML, Cohort 41141

[back to top]

Time to Hematologic Recovery

Time to Absolute Neutrophil Count > 1.0 x 10e9/L and Platelet Count > 100 x 10e9/L, whichever was later, for those patients who achieved a remission and achieved these hematologic goals. (NCT02440568)
Timeframe: Within 6 months of last dose of Omacetaxine

InterventionDays (Median)
Patients With Newly Diagnosed AML, Cohort 125.5
Patients With Newly Diagnosed AML, Cohort 235
Patients With Newly Diagnosed AML, Cohort 333.5
Patients With Newly Diagnosed AML, Cohort 436

[back to top]

Toxicity: Describe by the Adverse Events as Assessed by the CTCAE Grading

Describe the adverse events associated with Omacetaxine when administered in combination with cytarabine and Idarubicin as induction therapy for AML, using CTCAE grading (NCT02440568)
Timeframe: Up to 6 months after last dose of Omacetaxine

InterventionTotal Adverse Events (Number)
Patients With Newly Diagnosed AML, Cohort 147
Patients With Newly Diagnosed AML, Cohort 288
Patients With Newly Diagnosed AML, Cohort 3219
Patients With Newly Diagnosed AML, Cohort 437

[back to top]